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Abstract: Non-alcoholic fatty liver disease (NAFLD) is often the hepatic expression of metabolic
syndrome and its comorbidities that comprise, among others, obesity and insulin-resistance. NAFLD
involves a large spectrum of clinical conditions. These range from steatosis, a benign liver disorder
characterized by the accumulation of fat in hepatocytes, to non-alcoholic steatohepatitis (NASH),
which is characterized by inflammation, hepatocyte damage, and liver fibrosis. NASH can further
progress to cirrhosis and hepatocellular carcinoma. The etiology of NAFLD involves both genetic
and environmental factors, including an unhealthy lifestyle. Of note, unhealthy eating is clearly
associated with NAFLD development and progression to NASH. Both macronutrients (sugars, lipids,
proteins) and micronutrients (vitamins, phytoingredients, antioxidants) affect NAFLD pathogenesis.
Furthermore, some evidence indicates disruption of metabolic homeostasis by food contaminants,
some of which are risk factor candidates in NAFLD. At the molecular level, several models have
been proposed for the pathogenesis of NAFLD. Most importantly, oxidative stress and mitochondrial
damage have been reported to be causative in NAFLD initiation and progression. The aim of this
review is to provide an overview of the contribution of nutrients and food contaminants, especially
pesticides, to oxidative stress and how they may influence NAFLD pathogenesis.
Keywords: steatosis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH);
food contaminant; macronutrients; micronutrients; oxidative stress; mitochondria; reactive oxygen
species (ROS)
1. Introduction and Background
1.1. General Overview
Non-alcoholic fatty liver disease (NAFLD) frequently co-exists with metabolic syndrome and thus
often is defined as the liver expression of dyslipidemia, insulin resistance, and obesity. However, it can
also occur in patients with low body mass index (<25 kg/m2), a condition known as lean NAFLD [1–3].
NAFLD is characterized by fat accumulation in hepatocytes and comprises a spectrum of disease.
This spectrum ranges from simple steatosis (non-alcoholic fatty liver or NAFL) to non-alcoholic
steatohepatitis (NASH) with inflammation, hepatocyte ballooning, and various levels of fibrosis,
associated with a significant risk for progression to cirrhosis and liver cancer (hepatocellular carcinoma
(HCC)). In fact, only 20% of NAFLD patients develop NASH, and 4% of patients with NAFL and
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20% of patients with NASH develop cirrhosis [4]. Over time, up to 5% of patients with NASH will
experience spontaneous regression. NASH is strongly associated with the degree of hepatic fibrosis,
which is predictive of the overall mortality in patients with NAFLD [4].
NAFLD prevalence is increasing among children [5,6] and has become the most common chronic
liver disease in childhood and adolescence, as it is among adults. NAFLD affects approximately
25% of the global population [7], but the prevalence varies considerably by region. It is highest in
the Middle East (32%) and South America (30%) and lowest in Africa (13%). In North America and
Europe, the prevalence is 24%, and it is 27% in Asia [7]. As the overweight and obesity pandemic
drives the development of metabolic conditions promoting NAFLD, the health and economic burdens
continuously increase, also fueled by the boom in childhood obesity and an aging population [8,9].
NAFLD is defined as >55 mg triglycerides (TGs) per gram of liver or the presence of more
than 5% steatotic hepatocytes without histological damage or inflammation. Most commonly,
the percentage of hepatocytes presenting lipid accumulation is divided into three ranges: 5% to
33%, 34% to 66%, and >66%. Accordingly, the severity of steatosis is considered to be mild, moderate,
or severe, respectively [10]. NAFL can progress to NASH that is characterized, in addition to steatosis,
by ballooning degeneration of hepatocytes and lobular inflammation. The presence of perisinusoidal
fibrosis is generally not considered a prerequisite for NASH diagnosis [11]. A recent study has
found that some patients with NAFLD but without NASH may develop progressive fibrosis and
have an increased mortality risk regardless of their baseline NASH status [12]. Furthermore, fibrosis
progression is faster in lean patients with NAFLD, who can have a higher risk of developing cirrhosis
or HCC compared with NAFLD patients who are overweight [13]. This pattern suggests that once the
disease has progressed to NASH, obesity may not be the key factor in fibrosis progression [1], but this
association remains debated and needs further investigation.
1.2. Development of NAFLD
Multiple factors determine NAFLD progression, which has led to the proposed “multiple hit”
hypothesis [14]. These hits, which include nutritional factors and the gut microbiota, act in the context
of diverse genetic backgrounds. For several years, development of NAFLD was explained by the
“two hit” theory, according to which progression to NASH from “simple” steatosis or NAFL required
a second “hit,” such as oxidative stress and hepatocyte damage. Today’s perception of NAFLD is
that several different pathways can drive its development, resulting in a heterogeneous range of
manifestations characterized by liver and serum lipidomic signatures that reflect disease development
and progression. These variants allow for classification of NAFLD into different subtypes, based on the
impairments of key pathways that control fatty acid (FA) homeostasis [15]. Pathogenic drivers of NAFL
and NASH may arise because of the overwhelmed capacity of the liver to handle an overflow of the
primary metabolic energy substrates, carbohydrates, and FAs, leading to the production of toxic lipid
species [16]. The substrate overload liver injury model of NASH pathogenesis underscores the pivotal
role of free FAs (FFAs) in the disease process during which toxic metabolites promote hepatocellular
stress, cellular injury, and death. The activation of hepatic stellate cells and immune cells enhances the
fibrogenesis, inflammation, and genomic instability that predispose to cirrhosis and HCC. There are
two sources of hepatic free FFAs: lipolysis of TGs in adipose tissue with liver delivery through the
bloodstream, and de novo lipogenesis in hepatocytes, which converts excess carbohydrates, especially
fructose, to FAs and contributes to the accumulation of hepatic fat in NAFLD [17]. In hepatocytes,
these FAs are processed by mitochondrial beta-oxidation and re-esterification to form TGs that are
stored in lipid droplets or exported into the bloodstream, carried by very low-density lipoprotein
(VLDL).
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1.3. Determinants of NAFLD/NASH Development
1.3.1. Genetic Component
Clinical observations have unveiled a high variability in susceptibility to NAFLD, with some
patients exhibiting NASH and others having NAFL only, despite presenting with well-established risk
factors. This variability has been addressed in the last decade after findings revealed an important role for
differences in genetic background. A better understanding of the genetic basis of NAFLD should benefit
the development of new medications to treat advanced disease [18]. Several genetic polymorphisms
associated with NAFLD susceptibility implicate proteins regulating lipid and retinoid metabolism.
The most well-documented polymorphism is the Patatin-like phospholipase domain–containing
protein 3 (PNPLA3) isoleucine-to-methionine substitution at position 148 (rs738409C>G coding for
PNPLA3 I148M). This loss-of-function I148M variant protein has already been reviewed in several
publications [1,14,18,19]. PNPLA3 encodes the patatin-like phospholipase domain-containing protein 3,
a triacylglycerol lipase that mediates triacylglycerol hydrolysis in adipocytes and hepatic lipid droplets.
Significant associations have been identified between PNPLA3 I148M and liver fat, NASH, fibrosis,
cirrhosis, and HCC. PNPLA3 I148M accumulates on lipid droplets and evades ubiquitylation so that
its degradation is reduced. It remodels liver TGs and increases hepatic retention of polyunsaturated
FAs (PUFAs) [16,20]. Furthermore, PNPLA3 has a role in hepatic stellate cell activation in response to
fibrogenic stimuli and in the release of retinol by these cells [21].
The next important protein variant is the transmembrane 6 superfamily member 2 (TM6SF2)
guanine-to-adenine substitution at position 167 (rs58542926 E>K, coding for TM6SF2 E167K), which also
results in a loss of activity. TM6SF2 plays a role in loading TGs to apolipoprotein B 100 in the secretion
pathway of hepatic VLDL. Reduced TM6SF2 activity results in triacylglycerol entrapping in lipid
droplets [20,22]. Therefore, TM6SF2 E167K increases hepatic TG content while decreasing lipoprotein
levels in the serum. Individuals carrying the variant gene have a higher risk for NAFLD but lower risk
for cardiovascular disease [23]. Consistent with this finding, knockdown of Tm6sf2 in mice or transient
TM6SF2 overexpression alters the serum lipid profiles [24].
Another gene variant is that of the membrane-bound O-acyltransferase domain-containing 7
(MBOAT7) protein that incorporates arachidonic acid into phosphatidylinositol. In hepatocytes,
the rs641738 C>T MBOAT7 variant is associated with lower protein levels and changes in
phosphatidylinositol species in the plasma. It also is associated with NAFLD severity in individuals of
European descent, possibly resulting from changes in the remodeling of the liver phosphatidylinositol
acyl-chain [25]. In fact, this variant increases the risk for NAFLD, including inflammation and fibrosis in
white patients because of toxic accumulation of PUFAs as a consequence of their altered incorporation
into hepatocyte phospholipids [20,25], and HCC in individuals without cirrhosis [26].
Glucokinase regulatory protein (GCKRP) regulates de novo lipogenesis by controlling the flux of
glucose into hepatocytes. A missense loss-of-function GCKR variant (rs1260326, GCKR P446L) causes
hepatic fat accumulation through stimulation of glucose uptake into hepatocytes, which fuels de novo
lipogenesis [27,28].
Finally, polymorphisms within 17β-hydroxysteroid dehydrogenase type 13 (HSD17B13), a protein
expressed at the surface of lipid droplets with retinol dehydrogenase activity, are associated with
NAFLD, NASH, fibrosis, and cirrhosis [29,30]. Of interest, the effect of the HSD17B13 variant in
NAFLD is greater in carriers of the PNPLA3 I148M variant. This observation suggests that these two
risk factors interact in the pathogenesis of NAFLD. Both PNPLA3 and HSD17B13 regulate retinol
metabolism, which may suggest that this metabolism in hepatic stellate cells could be involved in the
pathogenesis of NAFLD [31]. These protein variants resulting from gene polymorphisms illustrate
clearly the genetic contribution to NAFLD susceptibility.
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1.3.2. Environmental Factors
In current Western societies, unhealthy diets, lack of exercise, smoking, and alcohol consumption
are typical lifestyle risk factors that contribute to NAFLD development [32,33]. In particular, excessive
fructose and saturated FA consumption, combined with sedentary lifestyles have contributed to the
global increase of obesity and NAFLD. Increasing epidemiological and experimental evidence also
suggest that exposure to some environmental contaminants, such as pesticides, participate in NAFLD
development and progression.
• Nutrients
The effects of NAFLD-associated gene polymorphisms, as noted above, indicate complex
interactions between genetic and environmental factors in the progression of NAFLD that are not yet
completely understood [34–36]. Lifestyle interventions and dietary factors offer benefits in patients with
NAFLD without obesity [37]. A healthy diet, together with physical activity, is commonly recommended
to patients with NAFLD to improve their condition. Weight loss significantly contributes to controlling
disease progression. However, despite clear documentation that dietary and exercise interventions are
effective, many patients fail to adhere to the recommendations for different reasons [1,38]. A recent
meta-analysis investigating the relationship between the risk for NAFLD in association with different
food groups (e.g., vegetables, fruits, red meat, fish, refined grains, whole grains, soft drinks) found
that red meat and soft drink intake is positively associated with NAFLD [39]. The impact of specific
diets on NAFLD is now well documented, such as the differences in the effects of Westernized versus
Mediterranean diets [1,38]. The Western diet (WD), which is particularly rich in saturated fat and added
fructose, is associated with a greater risk for and severity of NAFLD [40]. Diets characterized by a high
intake of so-called fast foods and rich in saturated FAs, trans-fats, simple sugars, red and processed
meats, full-fat dairy products, and soft drinks have a deleterious effect on the liver. In contrast,
Mediterranean-type diets, which are low in saturated fat and cholesterol and rich in monounsaturated
fats, polyunsaturated omega-3 FAs with a balanced ratio of omega-6 to omega-3 FAs, a high content
of complex carbohydrates, dietary fiber, and plant-based proteins, are beneficial to the liver and
associated with lower rates of NAFLD, NASH, and fibrosis [41–44]. A systematic review evaluating the
effectiveness of different dietary interventions recently showed that the Mediterranean diet is effective
for reducing hepatic steatosis [45]. This diet also can reduce liver fat without changes in weight and
may be particularly beneficial for patients with high genetic risk for NAFLD [46–48]. As might be
anticipated from these findings, greater adherence to the Mediterranean diet also is associated with
less severe NAFLD [49].
Among macronutrients, sugars such as sucrose and high fructose corn syrup significantly
increase risk for NAFLD and NASH [50]. Carbohydrates, especially fructose, stimulate de novo
lipogenesis, which accounts for 26% of increased FAs within the liver [51–53]. Among patients
with NAFLD, dietary fructose consumption, especially in sweetened beverages, is increased [54]
and associated with heightened inflammation and fibrosis [55]. Consistent with this observation,
very low-carbohydrate ketogenic diets decrease hepatic lipids and improve histologic parameters
including steatosis, inflammation, and fibrosis in people with obesity [56,57]. Dietary lipids are
involved in NAFLD but are not the main source of liver fat in NAFLD, as only 15% of hepatic lipids in
NAFLD patients trace to dietary fat [17]. Several studies have shown that high intake of saturated
lipids, cholesterol, simple carbohydrates, and animal proteins is a major determinant of NAFLD and
contributes to disturbances in energy homeostasis (lipid and glucose metabolism) and to hepatocyte
damage [58]. Of note, cholesterol is consistently elevated in human and mouse fibrotic NASH.
Its mechanistic link to NASH development has been explored recently [59]. Cholesterol upregulates
the transcriptional regulator TAZ (transcriptional co-activator with PDZ-binding motif) and promotes
fibrotic NASH through an adenylyl cyclase-calcium (Ca2+)-RhoA pathway. The importance of this
cholesterol–TAZ pathway remains to be demonstrated in human NASH [59].
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In contrast, dietary PUFAs and fibers have beneficial effects on NAFLD. Saturated FAs increase
fat accumulation in the liver, whereas the consumption of monounsaturated FAs (MUFAs) and PUFAs
has protective effects against NAFLD [60–62]. PUFAs inhibit hepatic lipogenesis through repression of
genes involved in lipid synthesis and glucose metabolism [63–65]. Epidemiological studies indicate
that patients with NASH tend to have a higher intake of saturated FAs and cholesterol, whereas their
PUFA consumption is lower compared to healthy controls [66].
A single oral dose of saturated FAs increases hepatic TG accumulation and impairs insulin
sensitivity in human and mouse liver [67]. Compared to fat and carbohydrates, the role of dietary
proteins in NAFLD pathogenesis is poorly studied and remains controversial. A recent study analyzed
the effects of isocaloric diets rich in animal proteins or plant proteins for 6 weeks in patients with diabetes
and NAFLD and found that both high-protein diets reduced liver fat [68]. However, high consumption
of proteins and of red and/or processed meat has been reported in patients with NASH [69,70].
The Rotterdam study further showed that a high animal protein intake is associated with a higher
prevalence of hepatic steatosis in overweight and elderly patients [71].
A role for micronutrients in NAFLD is less known, but the liver is important for their metabolism,
which is often disturbed in liver diseases. Several micronutrients, such as zinc, copper, iron, selenium,
magnesium, vitamins A, C, D, and E, and carotenoids have beneficial effects in NAFLD, mediated
by their lipoprotective, antioxidant, antifibrotic, and immunomodulatory properties. However,
the appropriate dosage appears to be important because an excess of iron and selenium may increase
the severity of NAFLD [38,72]. Hepatic iron accumulation in reticulo-endothelial cells occurs in
NAFLD and is associated with disease severity, but observations are often conflicting [73–77]. Similarly,
some studies have reported that iron depletion by phlebotomy leads to histological improvements and
liver enzyme normalization in NAFLD patients with hyperferritinemia, but results of several studies
do not support the use of phlebotomy in these patients [78–80]. A classic intervention in patients with
NAFLD is vitamin E supplementation because of increased oxidative stress. However, side effects,
including hemorrhagic stroke and prostate cancer, limit the clinical use of vitamin E. Interventions
with combinations of micronutrients are potentially interesting because experimental studies in
mice have indicated beneficial effects on liver steatosis, body weight gain and hypertriglyceridemia,
with findings suggesting that a cost-effective combinatorial micronutrient-based strategy could be
tested in humans [81,82].
Probiotics are widely used to promote human health as described in a recent review [83],
and prebiotics are nutrients used by host micro-organisms. They modulate the composition of the gut
microbiota involved in NAFLD development [84,85]. Impacts of probiotic-based therapies in NAFLD
patients are still debated. In one study, treatment of NAFLD patients with a combination of probiotics
and prebiotics for 1 year led to faecal microbiome changes without modification of liver fat content and
liver fibrosis markers [84]. In another study, NAFLD patients consuming a symbiotic food combining
prebiotics and probiotics for 24 weeks presented improved serum steatosis associated parameters and
oxidative stress biomarkers [86]. In a third study, treatment of Asian NAFLD patients with probiotics
and prebiotics caused a decreased body weight and an amelioration of NAFLD parameters [85].
In animal models, pro- and prebiotic treatments also improved NAFLD development. Rat fed
HFD containing the probiotic strain Lactobacillus mali APS for 12 weeks showed a decrease in body
weight gain associated with reduced hepatic lipid accumulation and increased antioxidant response;
these effects were associated with a decrease of some bacteria species [87]. Standard chow diet
enriched with prebiotics (oligofructose or dextrin) induced changes in rat redox status and serum
lipid biomarkers suggesting a positive impact of these prebiotics on NAFLD [88]. Cranberry extract
could be another promising prebiotic in NAFLD prevention and/or treatment. Mice fed a high fat/high
sucrose (HFHS) enriched with cranberry extract for 8 weeks improved all biomarkers of NAFLD [89].
Collectively, these results show that pre- and probiotics can ameliorate hepatic steatosis by modulating
lipid metabolism and antioxidant activity.
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The strong association between NAFLD and obesity further reinforces the role of dietary factors
in the pathogenesis of NAFLD. Hence, in the absence of an approved drug treatment, as noted,
a lifestyle intervention that targets weight loss is the primary therapy for the management of NAFLD.
The effectiveness of weight reduction was recently confirmed in a meta-analysis of 22 randomized
clinical trials that included more than 2500 patients with NAFLD. The results showed that weight loss
intervention always improved their serum and histologic parameters, although no changes in liver
fibrosis were observed [90].
In general, patients with NAFLD have a higher daily energy intake compared with healthy
controls [91], and calorie restriction leading to weight loss has beneficial effects in these patients [92].
Both acute and chronic calorie-restricted diets with either a low-fat or low-carbohydrate content are
associated with reduced liver fat in patients with obesity [93,94]. Hypocaloric diets are also effective in
improving NAFLD in patients with diabetes and children with obesity [95,96]. In experimental models,
calorie restriction extends lifespan and reduces the hepatic steatosis associated with obesity [92,97,98].
• Gut microbiota
Some nutrients known to promote NAFLD, such as fructose, affect the gut microbiota and cause
dysbiosis (an altered gut microbiota composition). These changes impair the permeability of the
gut barrier and trigger the development of metabolic syndrome and its associated perturbations.
In contrast, intake of dietary fiber, probiotics, and prebiotics associated with physical training is
effective in improving NAFLD [99–101].
Of note, the gut microbiota is also required for the hepatic clock daily oscillations that regulate
metabolic gene expression for optimal liver function [102–104]. In fact, the liver and gut are in close
anatomical and functional relation via the portal vein. Diet, gut microbiota, and the liver constitute
an axis that can promote either liver health or NAFLD progression. Analyses of the variations in gut
microbiota composition in NAFLD have identified specific bacterial species that directly impact NAFLD
progression [105]. In support of a beneficial effect, the administration of butyrate, a short chain FA
produced by the gut microbiota, improves hepatic inflammation and fat accumulation in NAFLD mouse
models [106]. However, despite many animal studies demonstrating a relationship between dysbiosis
and NAFLD, only a limited number of cross-sectional human studies have investigated the role of the
gut microbiota in NAFLD or NASH, with variable results [107]. Intestinal microbiota dysbiosis also
has been associated with other liver diseases in animals and humans, including alcohol-related liver
disease, cirrhosis, and HCC [107].
• Food contaminants: the example of pesticides
Pesticides are considered as risk factors for human health. Various epidemiological studies
reported a correlation between occupational exposure to these products and the development of
pathologies, such as cancers, neurodegenerative diseases, and metabolic disorders [108–111]. Moreover,
recent population studies (Nutrinetcohort in France) showed that the consumption of organic food
correlated with a significant decreased risk of metabolic disease and cancer [112–114]. In addition,
pesticides are bioactive compounds that exert an impact on various pathways underlying diseases [115].
Environmental contaminants are considered to play major roles in the etiology and progression of
NAFLD. Endocrine-disrupting compounds were first described as inducing reproductive disorders
but can be involved in the etiology of diabetes and other metabolic disorders independently of their
hormone signaling effects [116–122]. In addition to contaminants such as polychlorinated biphenyls
(PCBs), other compounds such as dioxins [123], bisphenol A [122], and pesticides are suspected to
contribute to the increased prevalence of NAFLD.
Organochlorine insecticide levels in serum from adult participants of the National Health and
Nutrition Examination Survey have been associated with increased odds ratios for alanine amino
transferase (ALT), which may indicate NAFLD [124]. It is noteworthy that most epidemiological studies
do not present information linking exposure to pesticide to NAFLD, but rather focus on diabetes and
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obesity [115,125]. In epidemiological studies, the serum concentrations of organochloride pesticides
have been significantly associated with diabetes, especially in women [126], with a specific metabolic
profile including mainly metabolites related to lipid metabolism [127], metabolic syndrome [128],
and adiposity [129]. However, no correlation was found between serum levels of the organochloride
dichlorodiphenyldichloroethylene (DDE) and the incidence of type 2 diabetes in a population of
adults living in urban India [130]. Persistent but also non-persistent pesticides currently in use
may also support the development of metabolic diseases [125,131–134]. Experimental studies have
allowed identification of the type of pesticides that promote fatty liver disease or changes in global
metabolic homeostasis in animal models [123], such as organophosphorus or neonicotinoid or
pyrethroid insecticides [135–146], triazine herbicides [147,148], glyphosate herbicides [149–153], or other
families [154,155] and fungicides [152,156–161] (Table 1).
Perinatal exposure to some pesticides has been correlated with metabolic changes [162], increased
insulin levels in newborns [163], and overweight in childhood [164,165]. Experimental studies
evaluating the consequences of pesticide exposure during the critical window of pre- and postnatal
development (pregnancy and lactation) confirm that early life exposure to pesticides may have a role
in metabolic disruption later in life (Table 1). A metabolic impact of perinatal exposure to pesticides in
animal models has been reported for insecticides, such as chlorpyrifos [140,166] and imidacloprid [142];
herbicides, such as glyphosate [150] and 2–4 dichlorophenoxyacetic acid (2,4-D) [155]; and pesticide
mixtures [167,168]. The metabolic consequences of early life exposure to organophosphate have
been reviewed previously [61,74,169]. Early life exposure to fungicides has been tied to metabolic
disturbances, reduced liver weight, and histopathological changes [170].
Pesticide exposure may lead to NAFLD through an impact on lipid metabolism by (i) modifying
FA uptake and efflux [171] and FFA transport, (ii) increasing lipogenesis [172–174] (Table 1), (iii) altering
oxidation pathways [175] (Tables 1 and 2), and (iv) interacting with nuclear receptors involved in the
control of metabolism [176–178]. Some pesticides may disrupt lipid metabolism [179,180].
Pesticides alter glucose metabolism through the activation of glucose uptake, glycogenolysis,
gluconeogenesis (for insecticides, see [136]; for diazinon or monocrotophos-treated animals,
see [181–183], or inhibition of the mitochondrial respiratory chain [184]. They also have exerted
effects through modulation of carbohydrate response element binding protein (Chrebp) gene
expression levels [185] and changes in the expression of peroxisome proliferator-activated
receptor (PPAR)β/δ and genes involved in glucose metabolism (FoxO1 and cAMP response
element-binding protein, Creb) [186]. Pesticides induce insulin resistance by acting on insulin signaling
pathways [187]. Liver inflammation was also reported upon exposure to organophosphorus [187,188],
organochlorine [189], neonicotinoid [142,143], and pyrethroid insecticides [144,145], and to triazole or
imidazole fungicides [190,191] (Table 1).
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Table 1. Metabolic impact of pesticide exposure in normal diet-fed animal models. Acceptable Daily Intake (ADI) values were from https://ephy.anses.fr/ and
https://ec.europa.eu/food/plant/pesticides/eu-pesticides-database/. ADI, acceptable daily intake; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
BW, body weight; CAR, constitutive androstane receptor; GD, gestational day; HFD, high-fat diet; IL1-β, interleukin-1 beta LDH, lactate dehydrogenase; MDA,
malonaldehyde; NOAEL, no observable adverse effect level; ND, normal diet; NF-kB, nuclear factor kappa B, PND, postnatal day; SOD, Super oxide dismutase; TG,
triglyceride, TNF-α, tumor necrosis factor alpha; ADI, Acceptable Daily Intake.




• ND-fed male rats
• Oral daily gavage with 15 mg/kg for
4 weeks
• Increased serum ALT and AST activity,





• ND-fed male rats
• Oral daily gavage with 200 mg/kg for
28 days
• Increased levels of lipid
peroxidation biomarkers




• ND-fed male rats
• Oral daily gavage with 27 mg/kg for
30 days
• Increased liver MDA levels
• Decreased liver glutathione levels,
superoxide dismutase, and
catalase activities
• Increased liver IL1-β, TNF-α, and





• ND-fed pregnant rats
• Oral gavage with 1, 2.5, or 4 mg/kg
BW/day from gestational day 7 to
postnatal day 21
• Increased adiposity and weight gain
only in males with 2.5
mg/kg chlorpyrifos
[140]
• ND-fed female rats
• Oral daily gavage with 1 or 3.5 mg/kg
BW/day during gestation and lactation
• Decreased offspring BW gain at PND 60
• Increased fasting glycemia
• Increased ALT activity
• Decreased plasma TG levels
• Change in microbiota composition
[166]
Organochlorine Endosulfan(0.006)
• ND-fed male mice
• Oral daily gavage for 2 weeks with
doses ranging from 0.5 to 3.5 mg/kg BW
• Weight loss
• Changes in various liver metabolic
pathways (energy, amino acid, and
lipid metabolism)
• Gut microbiota alteration
[134]
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Table 1. Cont.




• ND-fed female rats
• Oral daily gavage with 9 or 45 mg/kg
BW for 4 weeks
• Biomarkers of hepatotoxicity [141]
Imidacloprid
(0.06)
• ND-fed pregnant rats
• Oral daily gavage with 1/45th or 1/22th
LD50 from mating to gestation
and lactation
• Hepatic necrosis and inflammation in
the non-exposed second generation [142]
Thiamethoxam
(0.026)
• ND-fed male rabbits
• Oral daily gavage with 250 mg/kg BW
for 90 days





• ND-fed male rats
• Oral daily gavage with 15 mg/BW for
30 days
• Liver inflammation (increased levels of
serum and liver lipid
peroxidation biomarkers)
• Changes in antioxidant enzyme activity






• Pesticide-enriched diet at 0.02 mg/kg
BW/day
• One month before and during gestation
• Increased glucose, cholesterol, TG
levels and AST and ALT activity in
mothers and newborns
• Increased maternal BW and liver
weight in mothers
• Change in pup liver weight
• Increased liver inflammation and lipid
content in both dams and newborns
• Increased circulating and liver levels of
oxidative stress biomarkers and





• Pregnant female ND-fed rats
• Pesticide enriched diet (1.5 mg/kg)
• During gestation and lactation and for
5 months after weaning
• Reduction of body weight, food and
energy intake in offspring
• Increase in plasma glucose, urea
cholesterol and creatinine levels in both
male and female rats
• Increase in liver oxidative stress
[146]
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Table 1. Cont.




• ND-fed male rats
• Oral daily gavage with 6.2 or 31.1
mg/kg BW for 7, 30, 45, or 60 days
• Increased levels of hepatic stress
biomarkers (MDA, AST, ALT) and
antioxidant enzyme activities
• Increased liver TNF-alpha and
interleukin gene expression
[137]
• ND-fed male rats
• Gastric intubation with 1, 2, 4, and 8
mg/kg BW for 6 consecutive days
• Changes in the expression of genes
coding for xenobiotic metabolism




• HFD- and ND-fed male rats
• Oral exposure in drinking water
• 30 to 300 µg/kg BW/day for 5 months
• BW gain in HFD- and ND-fed rats
• Increased insulin levels in HFD-fed rats




• Pregnant ND-fed mice
• Oral exposure to 0.5% glyphosate
solution in drinking water during
gestation and lactation
• ND-fed male rats
• Oral exposure to 0.1 ppb Roundup
formulation (eq to 0.05 µg/L glyphosate)
in drinking water for 2 years
• Decreased body weight in offspring
PND7 and 21
• Increased lipid levels in offspring in
liver and plasma




Glycine derivate Glyphosate (0.5)
• ND-fed male rats
• Oral daily gavage with 5, 50, or 500
mg/kg BW for 35 days
• Increased levels of serum and
liver MDA
• Decreased liver SOD activity
• Increased liver catalase activity






• ND-fed male rats
• Oral daily gavage with 62.5, 125, or 250
mg/kg BW/day for 14 days
• Increased biomarkers of liver lipid
peroxidation and protein carbonylation
• Decreased antioxidant
enzyme activities
• Liver hyperplasia and swelling,
occurrence of pyknotic nuclei, activated
Kupffer cells and leukocyte infiltrations,
large cytoplasmic vacuolization and
dilatation in blood sinusoid
[154]
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Table 1. Cont.





• ND-fed pregnant rats
• Co-exposure through drinking water at
126 mg/kg BW from GD 14 to PND 14
• Observation at PND 14
• Decreased pup BW
• Decreased mother BW and liver weight,
but also in food and water intake
• Increased plasma ALT, LDH, and AST
activity in both pups and dams
• Increased MDA levels and antioxidant
enzyme activities in dams and pups







• ND-fed male mice
• Oral exposure to 30 mg/L in drinking
water for 4 weeks
• Increased levels of serum ALT, AST and






• ND-fed WT and humanized CAR
male mice
• Pesticide-enriched diet with 50 or
500 ppm
• Induction of CAR-dependent
gene expression
• Increased liver weight









• ND-fed male rats
• Pesticide-enriched diet: individual
compounds or mixture (NOAEL/100;
NOAEL; NOAELx10)
• Changes in the expression of hepatic
genes involved fatty acid and
phospholipid metabolism, cytochrome
P450, transporters (Abcb1a, Abcc3)
• In most cases, treatment with mixtures




• ND-fed male mice
• Pesticide-enriched diet with 25, 50, or
100 mg/kg BW daily for 4 weeks
• No significant changes in hepatic TG
• Dysbiosis and colonic inflammation [160]
Benzimidazole Carbendazim(0.02)
• ND fed male mice
• 0.1, 0.5, or 5 mg/kg BW per day in
drinking water for 14 weeks
• Increased intestinal fat absorption
• Reduced liver lipid synthesis
• Increased fat lipid storage
• Intestinal dysbiosis
• Inflammatory response in
various tissues
[191]
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Table 1. Cont.
Type of Pesticide Chemical Family Active Substance(ADI mg/kg BW/day) Experimental Model Metabolic Effects Refs.
Fungicide Sulfamide Tolylfluanid(0.1)
• ND-fed male mice
• Pesticide-enriched diet with 100 ppm
for 12 weeks
• Increased BW and adiposity, glucose
intolerance, and insulin resistance,
impaired circulating levels of leptin
and adiponectin, disturbed fat
oxidation and lipolysis in adipocytes
















• ND-fed pregnant female rats
• Oral gavage with total dose of 28, 104,
or 210 mg/kg/day of the mixture from
GD 7 to GD 17
• Analysis at 4 months of age
• Decreased birth weight in exposed
male offspring
• Increased leptin levels in
female offspring
• Variations
• Change in the expression of 3 genes in



















• ND-fed male and female mice
• Pesticide mixture-enriched diet,
exposure to the ADI of each pesticide
for 52 weeks
• Overweight and glucose intolerance
and steatosis in males
• Liver oxidative stress and alteration in






















• ND-fed pregnant rats
• Pesticide-enriched diet; exposure at a
nominal dose corresponding to the
same proportion as their respective
environmental exposure value (from
French use) from GD 4 to GD 21
• Decreased liver weight in dams
• Increased liver weight in male offspring
• Decreased liver lipid content in
male offspring
• Changes in liver metabolome (lipid
metabolism biomarkers) and serum
metabolome in fetuses
[168]
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Of interest, pesticide exposure and a high-fat diet (HFD) (Table 2) [136] interact to modify
their effect on metabolic homeostasis [194]. In fact, various chemical families of insecticides seem
to be involved, i.e., organochlorine, pyrethroid, neonicotinoid, and organophosphorus compounds
(Table 2 [148,184,185,195–210]). Moreover, HFD components may act as a vehicle for pesticides,
allowing them to reach target organs more easily, as proposed in [136,211]. This finding suggests that a
different bioavailability of pesticides in mice fed with an HFD versus normal chow diet may explain,
at least in part, dissimilar outcomes with pesticide exposure in different studies.
The fact that some pesticides have antimicrobial activity implies that they affect the composition
and metabolic functions of the gut microbiota and may be metabolized by the microbiota [212,213].
For example, the organochloride dichloro-diphenyl-trichloroethane (DDT) is converted to DDD by
the rat and human microbiota (Eubacterium limosum) [214]. When administered by oral gavage in
mice, DEE, a metabolite of DDT, impacts bile acid metabolism and reduces the relative abundance of
Bacteroidetes, Verrucomicrobia, and Actinobacteria, whereas that of Firmicutes and Proteobacteria
is increased. Furthermore, genes involved in bile acid synthesis are upregulated in the liver [215].
Many studies mainly using rats have analyzed the impact of other insecticides on the microbiota,
and important changes in its composition have been reported (reviewed in [213]). Relatively little
is known about how glyphosate, the most widely used herbicide worldwide, affects NAFL in terms
of gut microbiota, but glyphosate has a profound effect on both gut microbiota composition [216]
and metabolism [217] in rodents. Roundup, whose active compound is glyphosate, is suspected to
lead to greater alterations in the gut microbiota composition than glyphosate alone, alterations that
are similar to those reported in NAFLD, obesity, and systemic inflammation [213,218,219]. Finally,
fungicides also cause an important dysbiosis and, one of them, carbendazim, has been associated with
hepatic oxidative stress [220]. Overall, pesticides in general are associated with important dysbiosis
but the link among pesticides, dysbiosis, and hepatic oxidative stress in NAFLD is not well established,
and further studies are warranted.
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Table 2. Metabolic impact of pesticide exposure in high-fat diet-fed animal models. Acceptable Daily Intake (AD)I values were from https://ephy.anses.fr/ and
https://ec.europa.eu/food/plant/pesticides/eu-pesticides-database/. ADI value is not reported for some compounds due to insufficient data (organochlorine compounds,
prinomectin, moxidectin, GW4064, PCB). ALT, alanine aminotransferase; BW, body weight; FFA, free fatty acid; CPT, carnitine palmitoyl-transferase; FXR, farnesoid X
receptor; GD, gestational day; GIP, glucose-dependent insulinotropic peptide; GLP-1, glucagon-like peptide-1; HFD, high-fat diet; HOMA-IR, homeostasis model
assessment of insulin resistance. NEFA, non-esterified fatty acid; NOAEL, no observable adverse effect level; ND, normal diet; PCB polychlorinated biphenyl;
PP, pancreatic polypeptide; PUFA, polyunsaturated fatty acid; PND, postnatal day; SFA, saturated fatty acid; TG, triglyceride; UCP, uncoupling protein; VLDL, Very
low density lipoprotein; WT, wild type; ADI, Acceptable Daily Intake.
Type of Pesticide Chemical Family Active Substance(ADI mg/kg BW/day) Experimental Model
Effects of Pesticide Exposure on Diet-Induced
Metabolic Disorders Refs.
Insecticide Organochlorine DDE
• ND- and HFD-fed male rats
• Pesticide-enriched diet for 4 weeks
• Increase serum ALT and AST levels in ND
• Decreased serum TG levels and liver lipid
content in HFD fed animals
• Increased CPT activity oxidation and lipid
peroxidation in ND- and HFD-fed animals
• Hepatic oxidative stress in ND- and
HFD-fed animals
• Increased antioxidant enzyme activities more
in ND- than in HFD-fed animals
• Increased UCP2 mRNA levels in ND- and
HFD-fed animals
[203]
• ND- and HFD-fed male rats
exposed to 100 µkg/BW/day DDE in
drinking water for 12 weeks
• Increased accumulation in fatty acid (SFA and





• Oral gavage of ND-fed male mice
for 5 days
• One-week resting period
• Then oral gavage each week of ND-
or HFD-fed males for 13 weeks
• After 4 and 8 weeks on the HFD diet, increased
fasting hyperglycemia and liver steatosis
• At week 13, HFD-induced decrease in fasting




• Daily oral gavage of pregnant
female mice from GD 11 to PND 5
at 1.7 mg/kg BW
• ND- and HFD-fed adult female
offspring for 12 weeks
• Reduced body temperature and energy
expenditure and increased body fat in
offspring of ND mothers
• Compared to ND, further HFD-induced
reduction of body temperature
• HFD-induced changes in brown adipose tissue
gene expression
[206]
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Table 2. Cont.
Type of Pesticide Chemical Family Active Substance(ADI mg/kg BW/day) Experimental Model
Effects of Pesticide Exposure on Diet-Induced
Metabolic Disorders Refs.
Insecticide Organochlorine Chlordane
• ND- and HFD-fed male mice
(6 weeks)
• Oral gavage daily at 1.45 mg/kg BW
from week 4 to week 6
• No change in BW in ND- and HFD-fed animals
• Increase in HFD induced liver metabolic
perturbations (TCA cycle, tryptophan







• ND- or HFD-fed male mice
• Pesticide-enriched diet with 50, 500,
or 5000 µg/kg BW/day for 12 weeks
• Potentiation of HFD-induced BW gain, total
adipose tissue weight, insulin resistance [208]
Cypermethrin
(0.050)
• HFD-fed male mice
• simultaneously exposed to 50 µg/kg
BW/day cypermethrin in drinking
water for 20 weeks
• No change in BW
• Increased levels of serum FFA, hepatic
lipid, TG
• Increased liver de novo FFA and TG synthesis




• ND- and HFD-fed male mice
• Co-exposure by daily gavage with 5
mg/kg for 12 weeks
• Increased BW in both ND- and HFD-fed mice
• Impaired glucose metabolism and insulin
resistance in both HFD- and ND-fed mice
[209]
• ND- and HFD-fed male rats
• Co-exposure by daily oral gavage to
0.3 and 3 mg/kg BW for 9 weeks
• Increased weight gain in ND- but not in
HFD-fed rats
• Obliteration of the increase in plasma TG
caused by HFD
• Decreased plasma insulin, C-peptide, and
amylin concentrations in both the ND- and
HFD-fed rats
• Decreased plasma levels of leptin GIP and
GLP-1 and PP induced in HFD-fed rats
• Differential alteration of gut microbiota
composition according to the diet
[210]
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Table 2. Cont.
Type of Pesticide Chemical Family Active Substance(ADI mg/kg BW/day) Experimental Model





• ND- and HFD-fed male mice for
4 weeks
• Oral gavage with 2 m/kg BW/day
chlorpyrifos during the last 10 days
of the experiment
• No significant body weight increase in
HFD-fed animals
• No significant increase in plasma TG in
HFD-fed animals
• Decreased expression of genes involved in
liver lipogenesis in ND- and HFD-fed animals
[195]
• HFD- and ND-fed male mice for
4 weeks
• Chlorpyrifos (2 mg/kg) single oral
gavage at the end of the experiment
• Increased TG serum levels in ND fed animals
• Hypoglycemia in HFD-fed animals. [196]
Parathion
(0.0006)
• Subcutaneous injection of PDN 1–4
in rats at 0.1 and 0.2 mg/kg/day
once daily
• A 6 week HFD feeding of 15
week-old male and female rats
• Increased serum cholesterol levels in fasted
HFD-fed males
• Decreased serum NEFA levels in fasted
ND-fed females
• Enhancement of HFD-induced BW gain in
females exposed to 0.1 mg/kg/day parathion
• Decreased BW gain in HFD fed females




• Daily gavage of female rats with 2.5
mg/kg BW/day from pregnancy day
7 until lactation day 21
• Overfeeding of pups by decreasing
the number of pups per nest
• Analysis at PND 90
• Decreased BW in both animal groups at PND 1
• Decreased BW in overfed animals at PND 90
• Increased peritoneal and mesenteric fat mass
only in normal fed animals at PND 90
• Decreased energy intake in overfed animals
at PND90
• Increased fasting glucose in normal- and
overfed animals
• Increased fasting insulin in normal-fed animals
• Increased glucose intolerance and insulin
resistance in normal-fed animals
• Reversion of many of the programmed
postnatal overfeeding induced metabolic
disturbances at PND 90
[198]
Neonicotinoid Imidacloprid(0.06)
• ND- and HFD-fed male mice
• Pesticide-enriched diet
• Exposure to dose ranging from TDI
to NOAEL for 12 weeks
• Potentiation of HFD-induced weight gain,
insulin resistance, and adipocyte size and
impaired glucose metabolism
[199]
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Table 2. Cont.
Type of Pesticide Chemical Family Active Substance(ADI mg/kg BW/day) Experimental Model







• HFD-fed male mice simultaneous
exposed to 1.3 mg/kg B avermectin
analogs by intraperitoneal injection
for 14 days
• Suppression of HFD-induced metabolic
disturbances in mice by most compounds,




• HFD fed WT and FXR null mice
simultaneous exposed to ivermectin
by intraperitoneal injection at 1.3
mg/kg BW/day for 14 days
• Decreased serum levels of glucose and
cholesterol, high-density lipoprotein and
low-density lipoprotein and VLDL cholesterol
levels, in wild-type mice
• Ivermectin effects suppressed in FXR null mice
[201]
Fungicide Strobilurin Azoxystrobin(0.2)
• HFD-fed male mice for 13 weeks
• Oral gavage at 25 mg/kg BW/day at
week 8 for 5 weeks
• Reduction in BW
• Improvement of glucose tolerance
• Decrease liver TG accumulation





• HFD-fed male mice simultaneously
exposed to atrazine in drinking
water at 100 µg/kg BW/day for
20 weeks
• No change in BW
• Increased levels of serum FFA, hepatic lipids,
and TG
• Increased liver de novo FFA and TG
synthesis pathways
• Increased uptake of FFA from blood
[221]
• HFD- and ND-fed male rats
simultaneously exposure to
atrazine in drinking water with 30
to 300 µg/kg BW/day for 5 months
• Body weight gain in HFD- and ND-fed rats
• Increased insulin levels in HFD-fed rats
• Insulin resistance in ND- and HFD-fed rats
[148]
Mixture POP Organochlorine pesticide and PCBmixture
• Leptin-deficient ob/ob ND fed
male mice
• Oral gavage twice weekly for 7
weeks at environmentally
relevant levels
• Increased steatosis in ob/ob mice
• Increased hepatic triglyceride content in
ob/ob mice
[202]
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Other environmental factors can affect NAFLD development and progression. Although the effect
of active smoking on NAFLD development remained controversial [222] a recent systematic review
and meta-analysis from 20 observational studies revealed a slight but significant association between
active and passive smoking and NAFLD [223]. The link between a modest alcohol consumption with
NAFLD development is described in a very recent review [224].
• Aim of the review
There is currently no effective pharmacological therapy for the treatment of NAFLD. Weight loss,
achieved through lifestyle changes including diet modifications and exercise, remains the most effective
strategy for NAFLD management. However, these lifestyle interventions are difficult to maintain
for most patients. Vitamin E and the anti-diabetic agent Pioglitazone are the two classic therapies
currently used to treat NAFLD patients but they can both induce adverse effects and their benefit on
liver fibrosis is either absent or still not clear. Most of the other molecules that are under investigation
target the metabolic comorbidities of NAFLD such as obesity, insulin resistance, and dyslipidemia [225].
A better understanding of the development and progression of this complex pathology will allow the
development of novel therapeutic strategies for the treatment of NAFLD.
As is well known, alterations in lipid metabolism are key to the development of NAFLD and its
progression. They can affect different reactive oxygen species (ROS) generators, such as mitochondria,
endoplasmic reticulum (ER), and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
(NOX) [226]. Although many aspects of the contributions of these disturbances to NAFLD remain
unexplored, much progress has been accomplished in recent years. Knowledge is accumulating on how
increased ROS generation triggers changes in insulin sensitivity and the activity of key enzymes of lipid
metabolism, innate immune system signaling, and the level of inflammatory responses. Our review
addresses the mechanisms and consequences of excessive ROS production in the liver that drives
NAFLD progression, and the roles of nutrients and food contaminants in these processes (Figure 1).
Our discussion on the roles of oxidative stress on NAFLD development covers knowledge
gained from both animal models, mainly rodent models, and humans. It is important to keep in
mind, while reading the review, that rodents and humans NAFLD are not equivalent, although
the FDA encourages the use of appropriate animal models for developing new treatments against
pre-cirrhotic NASH [227]. The current animal models mimicking the progression of the human NAFLD
phenotype rely on genetic alterations, chemically induced liver damage or diets deficient in essential
nutrients. Therefore, they do not fully match, mechanistically and biochemically, the lifestyle-associated
NAFLD in humans [228]. There are several models used currently, each presenting advantages and
limitations [229,230]). A useful animal model, from a clinician’s view point, should reflect the
important metabolic deteriorations seen in human NAFLD patients including hyperglycemia and
insulin resistance, hyperlipidemia, and obesity with liver fat accumulation. Fatty liver should show
progression from simple steatosis to the inflamed liver stage with ballooning and fibrosis monitored
by histopathological examination and quantified by recognized scoring systems. The progression
should be relatively fast allowing the evaluation of candidate drugs and nutritional interventions.
Despite relentless efforts and the advances made in recent years, the ideal rodent model comprising all
desirable characteristics is not yet available. Therefore, studies in different models are necessary to
perform all the analyses required for a better understanding of human NAFLD progression.
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Figure 1. Factors involved in non-alcoholic fatty liver disease (NAFLD) pathogenesis. Multiple causes,
including metabolic factors, gut microbiota, and environ ental fact rs, operate in the context of the
specific genetic background of individuals for the development of non-alcoholic fatty liver disease
(NAFLD). Lipid overload induces lipotoxicity that affects different reactive oxygen species (ROS)
generators, such as mitochondria, peroxisomes, and endoplasmic reticulum (ER). As environmental
factors, solid and liquid foods and their contaminants contribute to ROS production. ROS generation
triggers changes in insulin sensitivity, the activity of key enzymes of lipid metabolism, innate immune
system signaling, inflammatory responses, and liver apoptosis. High levels of ROS enhance oxidative
stress, thus creating a vicious circle. Collectively, these conditions contribute to NAFLD development and
progression. Other abbreviations: NAFL, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis.
2. Methods
We performed a PubMed search of the literature. Studies that were not published in English or
published in the grey literature were excluded. We tried to focus on articles published during the last
10 years. We established a list of keys words (below) and combined them according to each author’s
dedicated chapter in order to get a representative overview of the literature. Each author reviewed the
chapter of the other co-authors. Furthermore the corresponding authors, worked on the homogeneity
and uniformity of the different chapters. The following lists of keywords were used:
(i) “Oxidative stress” OR “oxidative phosphorylation” OR “oxidation-reduction potential” OR
“reactive oxygen species” OR “ROS” OR “reactive nitrogen species “ OR “RNS” OR “redox stress”
OR “peroxidation” OR “free radicals” OR “lipotoxicity” OR mitochondria OR endoplasmic
reticulum OR glutathione OR antioxidant pathways OR Nrf2 OR SIRT OR SOD OR GPX
OR Catalase
(ii) “metabolic hepatitis” OR “metabolic liver” OR “Non Alcoholic Fatty Liver Disease” OR
“Nonalcoholic Fatty Liver Disease” OR “Fatty Liver” OR “Nonalcoholic Fatty Livers” OR
“Nonalcoholic Liver” OR “Nonalcoholic Fatty” OR “Nonalcoholic Fatty Liver” OR “Nonalcoholic
Steatohepatitis” OR “Nonalcoholic Steatohepatitides” OR “Steatohepatitides” OR “Nonalcoholic
Steatohepatitis” OR “cirrhosis” OR “carcinogenesis” OR “hepatocarcinoma” OR “hepatocellular
carcinoma” OR “carcinoma” OR “hepatoma” OR malignant hepatoma”
(iii) “mice” OR “mouse” OR “mus musculus“ OR “clinical studies” OR “therapeutic”
(iv) “pesticides” OR “herbicides” OR “insecticides” OR “fungicides” OR “plant protection product”
(v) “oxidant” OR “antioxidant” OR “diet” OR “cholesterol” OR “fructose” OR “nutrients” OR
“micronutrients”, “macronutrients” OR “fat” OR “western diet” OR “sugars” OR “fibers” OR
“vitamins” OR “fatty acid”.
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(vi) “Probiotic” OR “microbiota” OR “dysbiosis”.
3. Role of Oxidative Stress in NAFLD Pathogenesis
Oxidative stress is defined as an imbalance between the cellular levels of antioxidants and that of
pro-oxidants, including ROS and reactive nitrogen species (Figure 2), which causes cellular damage
and, in most cases, cell death. In healthy physiological conditions, cells maintain a basal level of ROS
to promote the balanced redox signaling required for various processes such as cell metabolism, cell
differentiation and survival, immune defense, and modulation of transcription factor activity and
epigenetic state [226]. Upon oxidative stress, the antioxidant enzyme superoxide dismutase (SOD)
generates hydrogen peroxide (H2O2) from the superoxide radical (O2.−), which is then processed to
oxygen (O2) and water (H2O) through glutathione peroxidase (Gpx) or catalase enzyme activities
(Figure 2) [231]. Within cells, ROS are mainly produced in the mitochondria, the peroxisomes, and the
ER, but cytoplasmic production of ROS also occurs. High levels of ROS alter these organelles, further
enhancing oxidative stress and creating a vicious circle.
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Figure 2. Role of oxidative stress in NAFLD. Lipid and cholesterol accumulation in hepatocytes causes
lipotoxicity, resulting in activation of different path ays involved in oxidative stress. Lipid entry and
alteration of mitoch ndrial Ca2+ homeostasis se lectron transport chain (ETC) dysfunction that
leads to mitochondrial reactive oxygen species (ROS) production, which in turn induces Sirtuin (SIRT)3
expression, protein 3-tyrosine nitration, mitochondrial DNA damage, and me brane depolarization.
SIRT3 and protein nitration also cause ETC dy function and exacerbate mitochondrial ROS production.
Mitochondrial biogenesis dysfunction additionally induces ROS production. Lipotoxicity activates
endoplasmic reticulum (ER) stress, leading to ROS production by (i) unfolded protein response
(UPR) activ tion, which stimulates C/EBP homologous protein (CHOP) expression and (ii) Ca2+
homeostasis dysfunction. ROS generation in cytoplasm is induced by nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase (NOX) enzyme activation, oxidized phospholipids (OxPL), several
cytochrome p450 enzymes (CYP450), and lipid peroxid ti n. ROS a cumulation in hepatocytes leads to
impairment of several pathways involved in NAFLD development, such as lipid metabolism, insulin
signaling, inflammation, and apoptosis. Other abbreviations: mtDNA, mitochondrial DNA; TCA,
tricarboxylic acid cycle; MDA, malondialdehyde; 4-HNE, 4-hydroxynonenal; SERCA, ER calcium
pump sarco/endoplasmatic reticulum Ca2+-ATPase; JNK, c-Jun N-terminal kinase; NF-κB, nuclear
factor-kappa B.
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3.1. Evidence for a Role of Oxidative Stress in NAFLD
Oxidative stress promotes activation of enzymatic or non-enzymatic-mediated antioxidant
mechanisms that counteract ROS production. Both clinical and experimental studies show that these
antioxidant pathways are modulated during NAFLD progression. In fact, activity of the antioxidant
enzymes SOD and Gpx increases in patients with NAFLD (Figures 2–5) [232]. In vitro, hepatic stellate
cells deficient for the glutathione peroxidase 7 (Gpx7) isoform present increased expression of profibrotic
and pro-inflammatory genes in response to FFA exposure. Consistent with these results, overexpression
of GPX7 in these cells decreases ROS generation and expression of profibrotic and pro-inflammatory
genes. In vivo, Gpx7 deficiency exacerbates choline-deficient, L-amino–defined, high-fat diet-induced
NASH fibrosis [233]. The expression of glutaminase 1 (GLS1) is increased in both NASH preclinical
mouse models and clinical NASH liver biopsies. GLS1 promotes glutamine fueling of anaplerotic
mitochondrial metabolism resulting in increased ROS production. In methionine choline-deficient
(MCD) diet-fed mice, GLS1 inhibition decreases hepatic TG accumulation by restoring VLDL TG export
and diminishes oxidative stress by lowering ROS production. GLS1 deficiency in this model is also
associated with decreased lipid peroxidation [234]. Paraoxonase-1 is a liver antioxidant enzyme that
hydrolyses peroxide and lactones associated with lipoproteins. In a cohort of 81 patients with NAFLD,
the serum Paraoxonase-1 concentration was decreased, which could reflect higher oxidative stress in
these patients [235].
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Figure 3. ROS production in peroxisomes. In peroxisomes, fatty acid (FA) oxidation leads to the
formati n of H2O2, which is decomposed t antioxidant enzymes GPX1, CAT, r peroxiredoxin
(PRX) 1 or 5, leading to the formation f O2 and H2 2 can react with XO t produce O2.−. Nitric oxide
synthase (NOS) interaction with L-arginine (L-Arg) leads to the formation of NO., which interacts with
O2.− to form ONOO−. ONOO− is converted by Prx5 to a peroxynitrite radical ONO.. SOD2 dismutates
O2.− to H2O2. The Fenton reaction also occurs in peroxisomes and leads to membrane damage.
The H2O2 is then exported to the cytoplasm, where it acts as a signaling molecule that exacerbates
oxidative stress. Other abbreviations: XO, xanthine oxidase; CAT, catalase; GPX1, glutathione
peroxidase 1; SOD, superoxide dismutase; Fe2+, ferrous iron; O2, oxygen; H2O, water; NO., nitric oxide;
ONOO−, peroxynitrite; HO., hydroxyl radical; ONO., peroxynitrite radical; O2.−, superoxide; H2O2,
hydrogen peroxide.
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which together with the absence of an mtDNA repair system, makes it more susceptible to damage 
[246]. Mitochondrial complex I dysfunction can also arise from mitochondrial protein 3-tyrosine 
nitration by peroxynitrite anion. Peroxynitrite originates from a combination of nitric oxide (NO .) 
with superoxide (O2.−), which are both elevated in ob/ob mice and in patients with NAFLD. In vitro, 
incubation of mitochondrial proteins from wild-type (WT) mice with peroxynitrite induces their 3-
Figure 4. ROS production in mitochondria. Acyl-CoA imported into the mitochondria is converted by
β-oxidation into acetyl-CoA, which enters the tricarboxylic acid cycle (TCA), resulting in the production
of nicotinamide adenine dinucleotide (NADH) and succinate. Mitochondria have two respiratory chains
composed of different complexes: (i) complexes I (NADH-ubiquinone oxidoreductase), III (cytochrome
b-c1), and IV (cytochrome c oxidase). Complex I reduces NADH to NAD+ and H+ after electron (e−)
release, and (ii) complexes II (succinate-quinone oxidoreductase), III, and IV. Complex II catalyzes
the dehydrogenation and oxidation of succinic acid into furamate and 2H2 after e−release. Released
electrons pass through complexes and other molecules in the mitochondria inner me brane ubiquinone
(Q) and cytochrome c (cyt c). Complex V (F1F0-ATP synthase) us s the chemios otic proton gradient
to power the yn sis of ATP from adenosine-diphosphate (APD) and Pi. In red: impairment of
the electron ransport chain results n the leakage of e− that react directly with oxygen to form the
superoxide anion radi al transf rm d in H2O2 thro gh SOD2 activity. H2O2 can react with Fe2+
to fo m OH. (Fenton reaction). H2O2 is processed into H2O and O2 by the antioxidant nzymes
GPX1 and catalase. Mit cho drial ROS production c us s oxidative mtDNA, lipid, a d protein
damage. Other abbreviations: CAT, catalase; GPX1, glutathione peroxidase 1; SOD2, superoxide
dismutase; Fe2+, ferrous iron; O2, oxygen; H2O, water; HO., hydroxyl radical; O2.−, superoxide;
H2O2, hydrogen peroxide; ATP, adenosine-triphosphate; Pi, inorganic phosphate; NAD+, nicotinamide
adenine dinucleotide; H+, hydrogen; mtDNA, mitochondrial DNA; GSH, glutathione; GSSG, oxidized
glutathione; ROS, reactive oxygen species.
The peroxisomal antioxidant enzyme catalase plays a key role in protecting cells from oxidative
damage by reducing H2O2 concentration (Figure 3). In HFD-fed mice deficient for catalase,
lipid accumulation and oxidative stress are exacerbated [236]. These mice develop an imbalanced
redox status in peroxisomes because of increased H2O2 levels, which in turn induces ER stress in the
liver. Catalase inhibition in HepG2 cells increases ROS production by peroxisomes, causing ER stress
and FA accumulation [237]. In line with this observation, human liver cells with impaired peroxisome
biogenesis show decreased ER stress, oxidative stress, and apoptosis [238].
Expression of genes encoding antioxidant enzymes and regulators of the glutathione pathway
(glutamate-cysteine ligase catalytic subunit, glutamate-cysteine ligase modifier subunit, GPX2) is
regulated by the transcription factor erythroid2-like 2 (Nrf2) [239]. Upon oxidative stress, Nrf2,
which is anchored in the cytoplasm via binding to Keap1, dissociates from it and translocates into
the n cleus, where it interacts with specific DNA sequences called antioxidant response elements
in the promoter of its target antioxidant enzyme genes [240]. Nrf2 expression is increased in the
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first stage of NAFLD in preclinical models [241], and pharmacological activation of Nrf2 in mice
fed a high-fat and high fructose diet decreases NASH parameters (insulin resistance, weight gain,
TG, ALT) via the transcriptional regulation of genes involved in inflammation, apoptosis, fibrosis,
ER stress, and oxidative stress [239]. Consistently, Nrf2 deficiency in mice fed an MCD or an HFD
promotes progression of steatosis to NASH by increasing oxidative stress, inflammation, and hepatic
FA accumulation [242,243]. In addition, Nrf2-deficient mice fed an HFD develop a more severe
NASH phenotype than their WT counterparts [241]. In in vivo and in vitro models of NAFLD,
the reduction of Nrf2 expression by microRNA is associated with a decreased expression of its
target genes, heme oxygenase, Sod2, and NAD(P)H dehydrogenase quinone 1 and an increase in
ROS production [244]. Nrf2 also directly affects lipid metabolism by activation of genes involved
in FA oxidation (acyl-CoA Oxidase 2, carnitine palmitoyltransferase 1), TG export (apolipoprotein
B), and the lipogenic transcription factor sterol regulatory element binding transcription factor 1
(Srebp-1) [239]. Nfr2 deficiency in HFD-fed mice diminishes phosphorylation of acetyl-CoA carboxylate
(ACC), a rate-limiting enzyme of hepatic FA synthesis, and thus increases its activity [241]. Collectively,
these data indicate that alterations in antioxidant pathways are associated with NAFLD, suggesting a
role of oxidative stress in disease progression.
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formation and super xide (O2.−) and hydrogen per xide (H2O2) release through electron transfer.
ROS production and ER stress activate the unfolded protein response (UPR), which leads to a decrease
in GSH. UPR is regulated by three transmembrane proteins: protein kinase RNA-like ER kinase (PERK),
activating transcriptio factor 6 (ATF6), a d inositol-requiring signaling protein 1 (IRE1), which promote
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(SERCA) activity, leading to calcium leakage and decreased mitochondrial electron transport chain
(ETC) activity, resulting in ROS production. Other abbreviations: O2, oxygen; FFA, free fatty acid;
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3.2. Mechanisms of Oxidative Stress in NAFLD
3.2.1. Mitoch ndri -Mediated Oxidativ Stress
Mitochondria are intracellular sites of oxygen (O2) consumption. In case of energy imbalance,
such as lipid accumulation, mitochondria ROS production increases considerably because of
mitochondrial respiratory chain alteration and a reduction in electron capture through various
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mechanisms discussed below (Figure 4). Generation of mitochondrial ROS results in impairment of
the mitochondrial membrane potential generated by proton pumps and activation of the JNK (c-Jun
N-terminal kinase) and AMPK (5’ AMP-activated protein kinase) pathways. All of these mechanisms
enhance oxidative stress and lipid accumulation and promote inflammation, thereby contributing to
the development of obesity and metabolic diseases, including NAFLD [245].
Mitochondrial ROS production results from dysfunction in complexes I and II of the mitochondrial
respiratory chain. Various mechanisms leading to this dysfunction and ROS production have been
described in NAFLD. In ob/ob mice, the quantity of mitochondrial respiratory chain complex I is
decreased. In this model, mitochondrial oxidative stress causes mitochondrial DNA (mtDNA) damage,
resulting in the reduction of mtDNA-encoded subunits of respiratory chain complex I. mtDNA is in the
mitochondrial matrix near the mitochondrial respiratory chain where most ROS are generated. Thus, it
is particularly prone to oxidative damage compared with nuclear DNA, which is more protected inside
the cell nucleus. Furthermore, mtDNA lacks protective histones, which together with the absence
of an mtDNA repair system, makes it more susceptible to damage [246]. Mitochondrial complex I
dysfunction can also arise from mitochondrial protein 3-tyrosine nitration by peroxynitrite anion.
Peroxynitrite originates from a combination of nitric oxide (NO.) with superoxide (O2.−), which are both
elevated in ob/ob mice and in patients with NAFLD. In vitro, incubation of mitochondrial proteins from
wild-type (WT) mice with peroxynitrite induces their 3-tyrosine nitration, which results in decreased
complex I activity and mitochondrial oxygen consumption. This decrease is amplified by reduced
expression of prohibitin, a protein that protects mitochondrial complexes against degradation [246].
Complex I or II activity is also regulated by the mitochondrial histone deacetylase sirtuin (SIRT) 3.
Mice fed an HFD have decreased SIRT3 expression, which results in a higher level of membrane
transport chain complex I acetylation, causing mitochondrial dysfunction. MCD-fed mice deficient in
SIRT3 develop more severe liver lesions, inflammation, and fibrosis compared with WT mice [247].
The proper functioning of the mitochondrial respiratory chain requires ATP, and in turn, impaired
ATP production leads to transport chain complex dysfunction. In NAFLD, oxidative phosphorylation
(OXPHOS) and the TCA cycle are disturbed, which causes impaired ATP production leading to an
alteration in mitochondrial respiration and ROS production. In patients with NASH, antioxidant
capacity and ATP production decreases, which enhances hepatocellular damage and insulin resistance,
promoting NAFLD progression [248].
Mitochondria are dynamic organelles, and fission and fusion are crucial for maintaining their
function under environmental stress. Both processes are regulated by specific proteins, Fis-1 and
Drp-1 for fission and Mfn-2 for fusion, which show decreased expression in WD-fed mice, suggesting
that mitochondrial dynamism is affected in NAFLD [249]. ROS accumulation in mitochondria leads
to modification of several mechanisms associated with oxidative stress and NAFLD development.
Phosphorylated JNK under lipotoxicity or ER stress conditions phosphorylates SH3-domain binding
protein 5 at the outer mitochondrial membrane, leading to the inactivation of mitochondrial c-Src,
which regulates the phosphorylation of respiratory chain components. This Src inactivation alters
electron transport, which promotes increased ROS release [250]. Phosphorylated JNK is also associated
with insulin resistance, which further suggests its involvement in NAFLD development [251]. Oxidative
stress induced in HFD-fed mice causes liver damage through mitochondrial membrane potential
alteration [245]. ROS accumulation in mouse models of NAFLD affects mitochondrial depolarization
potential through the formation of aldehydes (malondialdehyde [MDA] and 4-hydroxynonenal
[4-HNE]) by lipid peroxidation or an increase in mitochondrial sensitivity to Ca2+.
Mitochondrial depolarization is a dysfunction that appears early in NAFLD development and
contributes to mitochondrial homeostasis deregulation. In fact, WD-fed mice show mitochondrial
depolarization at an early stage of NASH, with an increased protein level of PINK1 (PTEN-induced
kinase 1), a mediator of mitochondrial autophagy (mitophagy), which is associated with mitochondrial
dysfunction. In these situations of mitochondrial depolarization, the mitophagic burden increases,
mitochondrial biogenesis declines, and mitochondrial depletion occurs after 2 to 6 months.
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These alterations are thought to be important in promoting steatosis, inflammation, and progression to
fibrosis [249].
The ROS H2O2, produced by mitochondria, activates AMPK through modification of the ATP/ADP
ratio [252], which further regulates antioxidant enzyme gene expression through Nrf2 activation [253].
The AMPK pathway may be activated by an antioxidant component Peroxiredoxin 5 (Prx5). Indeed,
in HepG2 cells exposed to FFAs, mitochondrial Prx5 activates the AMPK pathway to regulate the
activity of lipogenic enzymes (ACC, SREBP-1, FA synthase) [254]. AMPK stimulates glucose and FA
oxidation by induction of CPT-1 and acyl-CoA dehydrogenase expression via PPAR gamma coactivator
1-alpha and PPARα [253]. Thus, although the AMPK pathway represents a protective response against
oxidative stress and lipid accumulation, prolonged oxidative stress alters this pathway, leading to lipid
accumulation and further enhanced oxidative stress. A recent study showed that the AMP kinase
pathway is inhibited in NASH, leading to the activation of caspase 6-associated cell death [255]. Similarly,
other antioxidant responses may have deleterious effects. Early upregulation of uncoupling protein-2
(UCP-2) during steatosis protects hepatocytes against ROS production through ATP production,
whereas a further increase in UCP-2 during NASH leads to chronic ATP depletion [256].
Overall, in NAFLD, mitochondria are an important source of ROS because of alterations in
complex I and II activity that initially lead to the activation of antioxidant mechanisms. However,
during prolonged oxidative stress, these mechanisms participate in oxidative damage and enhance
mitochondrial oxidative stress, thus contributing to the development of NAFLD (Figure 4).
3.2.2. ER-Mediated Oxidative Stress
The ER is an organelle connected to the nuclear membrane in eukaryotic cells and is abundant
in hepatocytes because of their high metabolic activity. It has multiple functions including protein
synthesis, folding, modification, and trafficking, and synthesis of lipids and steroid hormones.
Alteration of ER homeostasis, i.e., ER stress, can induce oxidative stress (Figure 5). The ER stress
response is defined by activation of the unfolded protein response (UPR) pathway. Prolonged ER
stress increases the PKR-like ER protein kinase (PERK) and activated transcription factor (ATF) 6
pathways that both lead to ROS generation through the proapoptotic C/EBP homologous protein
(CHOP), a specific protein of the ER stress response (Figure 5). CHOP is involved in oxidative stress
induction in mouse models of type 2 diabetes and MCD-induced steatohepatitis [226,257]. Recently,
ER stress was shown to be involved in lipogenesis and in the transition of NAFLD to NASH through
caspase 2 induction [258]. ER also contributes to the regulation of calcium (Ca2+) homeostasis and
particularly Ca2+ storage in the ER lumen. In animal models of diabetes and obesity, the decreased
activity of the ER Ca2+ pump sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) in hepatocytes leads
to ER stress and induces apoptosis [257]. Moreover, impaired Ca2+ homeostasis in the ER induces
mitochondria dysfunction [226].
Other studies have provided evidence for the involvement of the Ca2+ flux in oxidative stress
and ER stress induction. In Buffalo rat liver (BRL-3A) cells exposed to a high FFA concentration to
mimic NAFLD, induction of oxidative stress stimulates transcription and translation of the protein
calcium release-activated calcium channel protein 1 (Orai1), a plasma membrane protein involved in
the Ca2+ cytosolic flux. The resulting increase in Ca2+ entry into the cell activates nuclear factor-kappa
B (NF-κB) signaling, which further exacerbates the Ca2+ flux, mitochondrial impairment, and ROS
generation, enhancing ER stress. Other mechanisms activated by lipid accumulation and Ca2+
homeostasis impairment in the liver also enhance ER stress in NAFLD. For instance, in a mouse model
of MCD-induced steatohepatitis, increased expression and activation of liver protein kinase Cδ (PKCδ)
are associated with ER stress activation. Similar results have been obtained in vitro in mouse hepatic
cells cultivated in a palmitic acid-enriched MCD medium. In addition, PKCδ deficiency reduces
MCD- and palmitic acid-induced ER stress activation, hepatic TG accumulation, and cell death [259].
These effects may involve CHOP, because in a human hepatic cell line (L02) exposed to palmitic acid,
PKCδ deficiency reduces ER stress through decreased CHOP expression. In this model, PKCδ silencing
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also increases SERCA activity, which improves Ca2+ homeostasis [260]. In HFD-fed rats, increased
plasma FFA is associated with increased expression of markers of oxidative stress and ER stress, as well
as Orai1 and NF-κB [261]. Mitochondria and peroxisome functional alterations also can induce ER
stress. For example, an imbalance in redox signaling in peroxisomes upon catalase inhibition induces
FA accumulation, which leads to ROS production and ER stress [237] (Figure 5).
To summarize, ER stress induced by lipid accumulation during NAFLD promotes ER ROS
production and calcium homeostasis disruption that both act to increase oxidative stress during disease
progression (Figure 5). ER stress also modulates expression of proteins involved in lipid and glucose
metabolism, thus contributing directly to hepatic lipid accumulation [262]. Finally, in addition to
mitochondria and ER, the peroxisomes, which are important in H2O2 production by peroxisomal FA
oxidation, contribute to oxidative stress in NAFLD (Figure 3) [226,237,238,263].
3.2.3. Cytoplasmic Production of ROS
Patients with NAFLD present with altered expression of cytochrome P (CYP)450 enzymes,
which are involved in detoxification, FA oxidation, inflammation, and oxidative stress (Figure 6) [264].
In these patients, for example, increased serum lipid peroxidation correlates with a higher level of
CYP4A11. In contrast, in the hepatocyte cell line HepG2 exposed to FFA, CYP4A11 inhibition led to
reduced ROS production associated with decreased lipid accumulation and reduced pro-inflammatory
cytokine levels, such as tumor necrosis factor α (TNF-α), interleukin (IL)-6, and IL-1β [265]. In HFD-fed
mice, CYP4A deficiency reduces hepatic ER stress, apoptosis, insulin resistance, and steatosis, suggesting
a role for CYP4A in NAFLD pathogenesis. CYP2E1, which is expressed in ER, mitochondria, and cytosol,
is increased in experimental models of NAFLD and in patients with NASH, resulting in ROS generation
and inactivation of SOD and catalase [236,266]. CYP2E1 has a high NOX activity that promotes lipid
peroxidation [265,266]. Furthermore, overexpression of CYP2E1 in mice is associated with severe
steatohepatitis and upregulation of antioxidant enzymes (SOD2, catalase, and GPX) [267]. CYP1A1
induces ROS production by the reduction of O2 to H2O2 and O2.−. It also has a role inω-hydroxylation
of PUFAs. The expression of CYP1A1 is enhanced in oleic acid-stimulated HepG2 cells. In these same
cells, CYP1A1 small interfering RNA inhibits lipid peroxidation, whereas overexpression of CYP1A1
stimulates lipid peroxidation and reduces SOD expression. Collectively, these observations unveil a
regulatory role for CYP1A1 in hepatic lipid peroxidation [264].
CYP450 epoxygenase-derived epoxyeicosatrienoic acids (EETs) are a class of lipid mediators that are
abundant in liver and that mediate cytoprotective and anti-inflammatory properties. A CYP450-induced
EET increase in HFD-fed mice protects against NAFLD progression. Moreover, overexpression of
the CYP2J2 leads to higher EET levels in serum that are associated with decreased hepatic TG
levels, inhibition of the NF-κB/JNK signaling pathway, and increased antioxidant enzyme levels.
Treatment of HepG2 cells with EET protects against palmitic acid-induced lipotoxicity, oxidative stress,
and inflammation [268].
In cytosol, ROS are also produced by many enzymes including xanthine oxidase (XO),
cyclo-oxygenase lipoxygenase, and NOX (Figure 6) [226,269,270]. NOX-mediated H2O2 production
causes liver damage [271] and induces a pro-inflammatory response [269]. Patients with NAFLD
have a higher NOX2 activity and increased NOX2-derived peptide, a marker of systemic NOX
activation [271,272]. In one cohort of children with NAFLD, NOX2 activity increased in parallel with
disease severity [271]. Furthermore, HFD-fed mice deficient in NOX2 develop steatosis but not NASH
because of reduced OXPHOS dysfunction [273]. In agreement with this finding, NOX2-induced cellular
oxidative stress causes inhibition of OXPHOS activity induced by FFA treatment [270]. Modulation of
NOX expression also has been reported in experimental models. HFD-fed mice fed have increased
NOX expression and activity [273], and NOX1 expression is increased in a mouse model of obesity [274],
leading to ROS generation associated with nitrotyrosine protein expression that counteracted oxidative
damage [275]. NOX1 also induces ROS production in a mouse model of steatosis [274].
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O2.− utation by the antioxidant enzyme superoxide dismutase (SOD) forms hydrog n peroxide
(H2O2), which is decomposed to O2 and water ( 2 ) by the enzyme catalase (CAT) or the enzyme
glutathione peroxidase 1 (GPX1), leading to the oxidation of reduced GSH into glutathione disulfide
(GSSG). Reactive nitrogen species (RNS) are derived from nitric oxide (.NO) and superoxide (O2.−)
produced via specific enzymes such as NADPH oxidase; the reaction of .NO with O2.− produces
peroxynitrite (ONOO−). ONOO− can react with other molecules to form additional types of RNS
including nitrogen dioxide (NO2.) as well as other types of chemically reactive free radicals (.OH).
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In humans, NOX4 mRNA expression is upregulated in the liver of patients with N SH [275,276].
The NOX4 single nucleotide polymorphism rs3017887 is associated with increased ALT levels in
liver biopsies from patients with NAFLD, indicating hepatocyte damage [269]. In a mouse model of
diet-induced NAFLD, hepatocyte-specific deletion of NOX4 or its pharmacological inhibition reduces
oxidative stress and fibrosis. Cell culture findings show that NOX4 promotes oxidative stress by ER
stress activation [276]. In summary, increased NOX isoform expression and activity are associated
with NAFLD and lead to oxidative stress induction via ROS generation concomitant with activation of
ER and mitochondrial stress (Figures 4 and 5).
Oxidized phospholipids (OxPLs) play a role in oxidative stress induction through generation of
cellular ROS, which promote fibrosis and inflammation that result in NASH rogression. OxPLs are
produced upon overnutrition or in patients with NAFLD. Treatment of primary hepatocytes from
Ldlr−/− hyperlipidemic mice with an OxPL mixture promotes ROS accumulation in the cytoplasm and
all organelles, resulting in mitochondrial dysfunction [277]. Treatment of the immortalized human
hepatic stellate cell line with OxPLs stimulates fibrogenic gene expression [278]. Furthermore, in a
mouse model of NASH, the neutralization of OxPL decreases inflammatory mechanisms [277]. Toll-like
receptor (TLR)-4 and TLR-2 are expressed in Kupffer cells and stellate cells, which are associated with
fibrosis. Mice fed an HFD supplemented with lecinoxoids (synthetic OxPLs), which inhibit these
TLRs, show reduced liver fibrosis and inflammation (reduced IL-1B and IL-6) [279]. Furthermore,
the neutralization of OxPL in a mouse model of NAFLD inhibits progression to HCC [277].
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Iron metabolism, which is modified in patients with NAFLD [75,280–282], leads to ROS generation
because of the ability of the ferrous iron to catalyze the production of OH− from H2O2, known as the
Fenton reaction [257] (Figures 2–4). This point is further developed below in Section 5.
3.2.4. Gut Microbiota and Liver Oxidative Stress
Mice lacking the gut microbiota (germ-free mice) display an altered hepatic pool of glutathione [283].
The gut microbes also alter levels of amino acids and N-acetylated amino acids circulating in the mouse
portal vein, affecting host amino acid and glutathione metabolism in the intestine and the liver [284].
A recent study showed that the gut microbiome induces the Nrf2 antioxidant response pathway in
the liver [285] and that exogenous administration of Lactobacilli could amplify this response and
protect against oxidative liver injury. Of great interest, these authors identified a Lactobacilli-derived
metabolite (namely 5-methoxyindoleacetic acid) that could activate hepatic Nrf2 and in part mediate
these beneficial effects. The relevance of this gut–liver mechanism in humans remains to be studied.
Unhealthy eating modifies the gut microbiota, as others have reviewed [286,287]. This dysbiosis
participates in the development of metabolic diseases and plays a major role in NAFLD
pathogenesis [288,289]. In fact, the development of NAFLD correlates with (i) dysbiosis; (ii) a leaky
intestinal barrier; (iii) impaired mucosal immunity; (iv) bacteria and bacterial components reaching
the liver through the portal vein, as well the bacterial metabolites such as lipopolysaccharides,
trimethylamine-N-oxide, N,N,N-trimethyl-5-aminovaleric acid, and endogenous ethanol; and
(v) impaired bile acid homeostasis [286,287]. These alterations participate in increased hepatic
inflammation and oxidative stress and promote NAFLD development and progression to NASH.
Altogether, whereas the role of oxidative stress in NAFLD pathogenesis has been demonstrated
in both clinical and animal studies, the underlying mechanisms are complex and not completely
understood. Alterations in mitochondrial respiratory complex activity because of lipid accumulation
in NAFLD make the mitochondria the main source of ROS in this condition. ER stress, cytochromes,
NOX, and OxPLs are also key components in ROS generation. The consequences of ROS production
in NAFLD are enhanced oxidative stress and altered lipid metabolism, which further promote
lipid accumulation. In addition, increased ROS production may modulate insulin signaling and
inflammatory processes, thus promoting insulin resistance and inflammation, which are important
features of NAFLD progression [226] (Figure 2); however, the specific mechanisms underlying oxidative
stress–promoted NAFLD need further study. Furthermore, several environmental factors, such as the
nutrients and contaminants discussed below, affect oxidative stress in NAFLD.
4. Oxidative Stress in NAFLD: Role of Nutrients
An unhealthy lifestyle is strongly associated with NAFLD. Of note, dietary constituents are
key factors in NAFLD pathogenesis. Such factors include a high intake of calories and an excessive
consumption of saturated fats, refined carbohydrates, and animal proteins. Several nutrients are
well known to affect the metabolic pathways leading to hepatic fat accumulation in the first steps of
NAFLD development. Accumulating data also support the idea that diet-mediated alterations include
increased ROS production and oxidative stress, which are key factors in the progression of NAFLD
to NASH, as noted above (Figure 7). Given the essential role of nutrition in the etiology of NAFLD,
several epidemiological studies have evaluated its association with dietary habits.
4.1. Dietary Oxidants in NAFLD
A correlation between consumption of different nutrients and oxidative stress has been previously
shown in patients with NASH. Intake of saturated fat is associated with a lower ratio of reduced to
oxidized glutathione (GSH/GSSG), suggesting a pro-oxidant effect. In contrast, consumption of fiber,
MUFAs, PUFAs, vitamin E, selenium, and folate protect against oxidative stress [290].
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Figure 7. Role of nutrients in hepatic ROS production. High intake of diets rich in fructose or cholesterol
promot s hepatic xidativ stress. Fructose metab lism leads to adenosine triphosphate (ATP) depletion
and uric acid production, which both trigger reactive oxygen species (ROS) generation in the liver. High
fructose consumption can also cause gut dysbiosis, which influences the liver oxidative status. Dietary
cholesterol induces mitochondrial dysfunction and further mitochondrial ROS production. In contrast,
several micronutrients such as vitamins, polyphenols, carotenoids, some amino acids (glycine, serine),
and others have antioxidant properties and may be beneficial in NAFLD. Other abbreviations: ADP,
adenosine diphosphate; F1P, fructose-1-phosphate; Nrf2, nuclear factor erythroid-2-related factor 2;
GSH, reduced glutathione; FAs, fatty acids; PUFAs, polyunsaturated fatty acids.
HFDs induce obesity, insulin resistance, and hepatic steatosis. As noted above, an excess of lipids
in hepatocytes is associated with lipotoxicity and mitochondrial overload, resulting in impaired FA
catabolism and ROS production. Increased exogenous FA delivery by liver perfusion or by HFD
increases mitochondrial oxidative metabolism, resulting in hepatic oxidative stress during NAFLD in
mice [248]. Of interest, FA storage as TG, which avoids accumulation of hepatic FFAs, protects against
hepatic lipotoxicity and oxidative stress [291]. In line with this observation, the level of TG and free
cholesterol increases in the liver in patients with NAFLD, whereas the level of FFAs is unaltered [292].
A limited number of studies have assessed the relationship between dietary saturated FA intake and
oxidative stress. Medium-chain saturated FAs have shown antioxidant effects in rats through reduced
lipid peroxidation and increased activity of antioxidant enzymes [293,294]. In contrast, saturated FAs
in the steatotic rat liver induce hepatocyte ER stress and apoptosis [295]. In elderly Japanese patients,
a correlation has been reported between high consumption of saturated FAs, particularly short-chain
saturated FAs and medium-chain saturated FAs, and decreased urinary 8-hydroxy-2’-deoxyguanosine
(an oxidative stress marker) and ameliorated hypertension [296]. Overall, the effect of saturated FAs
on oxidative stress in NAFLD remains unclear and needs further investigation. Differences in FA
chain lengths may contribute to differences in their effects on oxidative stress: short-chain saturated
FAs and medium-chain saturated FAs may be antioxidant, whereas long-chain saturated FAs increase
oxidative stress.
In addition, a high ratio of omega-6 to omega-3 FAs reduces mitochondrial respiratory functions
and increases ROS levels in human hepatoma cells. Decreasing this ratio prevents diet-induced NASH
and hepatic oxidative stress in rats [297,298].
FAs are not the only compounds that accumulate in the mitochondria. Cholesterol is consistently
elevated in human and mouse fibrotic NASH, and its mechanistic link to NASH development has
been explored recently [59]. In hepatocytes from a NAFLD rat model, mitochondrial cholesterol
accumulation decreases mitochondrial glutathione, which is crucial for scavenging ROS produced
during mitochondrial metabolism, and sensitizes mitochondria to inflammatory cytokines [299].
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Mice fed a high-cholesterol diet show a modified transcriptome, including modulation of several
pathways involved in cell death and oxidative stress. Cholesterol accumulation increases ROS
generation, leads to expression of antioxidant genes such as SOD2, and modifies expression of
genes regulating the glutathione pathway (decreased GPx-1, increased GPx-4) [300]. In addition,
oxidation of free cholesterol generates oxysterols, which are elevated in NAFLD and may participate
in lipid synthesis and inflammation [301]. In patients with NASH, cholesterol accumulation decreases
mitochondrial membrane permeability and induces defective mitochondrial GSH transport from
cytosol to the mitochondria [256].
Interactions among different lipid classes may play a role in oxidative stress induction. For example,
dietary fat and cholesterol act in synergy to promote NAFLD progression through impairment of
mitochondrial function and biogenesis. Mice fed a high-fat, high-cholesterol diet develop more severe
liver lesions, including inflammation and fibrosis, and show mitochondrial dysfunction such as altered
respiration, increased H2O2 production, and impaired ATP homeostasis, compared to each diet (high fat
or high cholesterol) fed separately [302,303]. The combination of dietary cholesterol with PUFAs leads
to high levels of oxidized peroxiredoxins and protein carbonyls, indicating severe hepatic oxidative
stress [304]. Of interest, a ketogenic diet increases rat liver antioxidant capacity [305].
In the liver, fructose is mainly metabolized by fructokinase, which uses ATP to phosphorylate
fructose into fructose-1-phosphate. Thus, fructose metabolism decreases ATP levels, resulting in
oxidative stress induction and uric acid generation, which also has pro-oxidative effects [50,306].
Fructose drinking in rodents also induces gut microbiota changes and CYP2E1-dependent intestinal
oxidative stress, which both lead to endotoxemia and increased severity of steatohepatitis with
fibrosis [307]. Rats fed a diet rich in fructose for 3 weeks show decreased catalase activity and
GSH levels in the liver, whereas the level of NOX and the content of protein carbonyl groups,
a marker of oxidative stress, are increased [308,309]. These effects are associated with changes in
carbohydrate metabolism and increased hepatic TGs, suggesting a switch towards lipid synthesis
rather than mitochondrial oxidation, which may protect against ROS production [309]. A fructose-rich
diet also causes oxidative damage to hepatic lipids, proteins, and mitochondrial DNA, as shown
by increased lipid peroxidation and nitrotyrosine levels in the liver and higher levels of plasma
8-hydroxydeoxyguanosine generated by oxidative damage to DNA. In addition, administration of
the antioxidant lipoic acid or an inhibitor of NOX protects against fructose-induced hepatic insulin
resistance, oxidative stress, and inflammation, reinforcing the relationship between hepatic oxidative
stress and high fructose intake [308,310]. Fructose intake also enhances hepatic oxidative stress of
maternal HFD offspring because of decline in the antioxidant defense system [311].
In patients with NASH and hyperferritinemia, iron reduction by a combination of iron-restricted
diet and phlebotomy reduces serum iron and ferritin levels, liver enzymes, and hepatic oxidative
damage to DNA [312]. In preclinical models, iron excess leads to hepatic TG accumulation, but the
effect on oxidative stress is controversial. For example, dietary iron supplementation enhances
HFD-induced hepatic steatosis and inflammation, whereas no change in hepatic oxidative stress is
observed [313]. In contrast, iron supplementation in genetically obese mice causes hepatocellular
ballooning and hepatic oxidative stress by increasing lipid peroxidation and decreasing expression
of antioxidant genes [314]. A recent study indicated that the hepatocyte-specific deletion of the iron
chaperone, poly r(C) binding protein 1 (PCBP1), results in liver iron depletion, hepatic steatosis and
inflammation, increased lipid peroxidation, and activation of the Nrf2 and glutathione pathways.
Both an iron-restricted diet and treatment with vitamin E can prevent steatosis and hepatocyte damage
associated with PCBP1 deficiency, suggesting that iron mediates its toxic effects in part through the
production of ROS [315]. Liver biopsies of 222 patients (men and women) with NAFLD showed that
serum ferritin levels, which are biomarkers of iron metabolism, are positively associated with a higher
NAFLD activity score [316]. The relation between ferritin level and NAFLD is mostly significant in men
and associated with hepatic iron deposition, fibrosis, and NASH [77,317]. A correlation between ferritin
level and NAFLD development also has been observed in a cohort of postmenopausal women [317].
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Collectively, observations from dietary interventions show that cholesterol and fructose promote
oxidative stress in NAFLD pathogenesis. Meat processing of meat also causes protein oxidation,
which may be associated with oxidative stress [318]. In addition, the interactions among different
types of lipids may play a role in the induction of oxidative stress during disease development.
The pro-oxidant effects of saturated lipids, animal-based proteins, and iron are not well understood
and need further investigation in experimental and large-scale clinical studies. Although excess
of certain nutrients is clearly associated with oxidative stress induction in NAFLD, other nutrients
have antioxidant properties. Below, we discuss the antioxidant role of these nutrients in preventing
NAFLD development.
4.2. Dietary Antioxidants in NAFLD
Several meta-analyses have demonstrated the effectiveness of omega-3 PUFA supplementation in
the dietary management of NAFLD, especially for liver fat content, although a detailed mechanism of
its effect on liver inflammation and fibrosis is still unclear [319–323]. Omega-3 PUFAs reduce liver
TG accumulation mainly through regulation of hepatic lipid metabolism and inflammation [324].
In experimental studies, supplementation with omega-3 PUFAs, such as eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA), reduces HFD-induced steatosis in part through induction of
antioxidant responses [325]. Furthermore, omega-3 PUFA supplementation reduces hepatic oxidative
stress in HFD-fed mice, as shown by a decreased GSSG/GSH ratio and protein carbonylation content in
the liver [326]. Omega-3 PUFA supplementation also reduces the WD-induced NOX pathway [327]
and can decrease oxidative stress through indirect mechanisms such as Nrf2 upregulation because the
oxidation products of DHA and EPA are potent Nrf2 activators [328]. Dietary DHA is more efficient
than EPA in reducing WD-induced NASH and hepatic oxidative stress [327,329]. In humans, the effects
of PUFAs on oxidative stress in NAFLD are less clear. According to a recent systematic review of
clinical trials, the effect of omega-3 PUFAs on oxidative stress in human NAFLD is inconclusive and
varies from study to study depending on the oxidative stress marker measured [323].
MUFAs are the main FAs found in extra-virgin olive oil, which is associated with the prevention of
diet-induced liver oxidative stress [330]. However, a specific mechanism is unknown, and antioxidant
compounds such as phenols, which are present in high quantity in extra-virgin olive oil, are more
likely responsible for these beneficial effects [331].
A few dietary amino acids affect NAFLD pathogenesis in several ways, including gut epithelium
integrity, inflammation, fibrosis, and glucose homeostasis. We will only briefly address amino acids
here because a recent review has described their effects in some detail [332]. Branched-chain amino acids
repress inflammation, apoptosis, and fibrosis by downregulation of the transforming growth factor-β
and Wnt/β-catenin pathway, and steatosis and mitochondrial dysfunction by downregulating FA
synthase and upregulating mTOR. Glutamine attenuates inflammation by upregulating PPARγ.
The α-amino acids citrulline and arginine downregulate TLR-4, TNFα, IL-6, and endotoxins,
which ameliorates inflammation and apoptosis, and serine increases AMPK activity to repress
steatosis and mitochondrial dysfunction. Serine is also a GSH precursor, and its supplementation has
been reported to decrease hepatic steatosis in a proof-of-concept human study [333]. Of interest, glycine
supplementation increases thermogenic activity in hepatic mitochondria, mitigates liver steatosis,
improves insulin sensitivity, and reduces serum lipid levels by repressing p38, JNK, and TLR-4,
and increasing glucagon-like peptide-1/glucagon [332]. Methionine also has an important hepatic
impact because compromised levels in methyl-group donors result in alterations promoting the
development of NAFLD in animal models and humans. In mice, both dietary methionine deficiency
and high methionine supplementation induce anomalies associated with NAFLD progression, including
an effect on lipid metabolism and one-carbon metabolic pathways disturbances. Oxidative and ER
stress is also increased [334].
Choline, which is not an amino acid, is also an essential methyl donor, and its deficiency results
in impaired VLDL secretion and hepatic fat accumulation and liver damage, including impaired
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mitochondrial function. The result is reduced FA oxidation and stimulated production of ROS with
downstream deleterious effects. Of interest, the MCD diet has become a classical diet for triggering
NASH. The absence of two main ingredients, methionine and choline, alters mitochondrial β-oxidation
and VLDL synthesis [335], causing relatively rapid fatty liver development, together with oxidative
stress and modifications in NASH-promoting adipokine and cytokine profiles, contributing to liver
injury [336]. MCD-fed rodents undergo significant weight loss and present with decreased serum TG,
cholesterol, glucose, insulin, and leptin [337]. These effects are a limitation of this diet model because
the metabolic profile it induces is very different from that of human NASH, which must be considered
when using the MCD in studies [338].
Taurine is a sulfur-containing β-amino acid that is not used for protein synthesis. The main
sources of taurine are fish, meat, and dairy. It has several health benefits, and people also take it
as a supplement to improve physical performance. In a mouse NAFLD model, taurine treatment
alleviated HFD-induced reduction of catalase and SOD activity, and, in HepG2 cells, it suppresses
FA-induced lipid accumulation and reduces ROS production in concert with the FA-induced alteration
in mitochondrial membrane potential. These findings supporting an antioxidative effect of taurine
show that it can attenuate NAFLD progression in animals [339].
Micronutrients are required in microgram or milligram quantities for physiological functions,
such as cellular metabolism and tissue function [340]. These compounds, including vitamins, minerals,
and phytochemicals, are also important in NAFLD pathogenesis [72,341], mainly through modulation
of anti-inflammatory and antioxidant pathways. Liver plays an essential role in micronutrient
metabolism by contributing to their uptake, transport, and storage, and by producing binding,
transport, and regulatory proteins required for their action at the cellular level [72]. Micronutrients
with antioxidant capacity include vitamin D, vitamin E, and phytochemicals such as carotenoids
and polyphenols.
Vitamin D is often deficient in liver diseases and is associated with NAFLD and NASH in
epidemiological studies. In fact, the anti-inflammatory, antifibrotic, and antiproliferative effects
of vitamin D on NAFLD and NASH have been documented in both human cohorts and animal
models [342–345]. Preclinical models have provided critical information for designing possible related
therapeutic strategies for the treatment of NAFLD/NASH [342].
Vitamin E supplementation in adults with NAFLD does not improve fibrosis but ameliorates
hepatic steatosis and inflammation [346]. Animal studies show that vitamin E improves NAFLD/NASH
by repressing oxidative stress and inflammation [347]. We have recently reviewed the impact of
vitamin E on NAFLD/NASH more extensively [348].
Natural polyphenols found in vegetables, fruits, coffee, and wine are a class of phytochemicals
that include several different compounds sharing a common phenolic structure. They are classified as
flavonoids and non-flavonoids. Their beneficial effects mainly trace to their antioxidant properties,
and they also influence glucose and lipid metabolism and exert anti-inflammatory, antifibrogenic,
and antitumoral effects [349]. In addition, they reduce de novo lipogenesis by regulating the activity
of SREBP-1c and stimulate FA β-oxidation possibly via activation of AMPK [350]. Furthermore,
several compounds of the polyphenol family, including green tea catechins, curcumin, resveratrol,
and quercetin, appear to reduce liver enzymes, lipid peroxidation, and inflammation markers [342].
Carotenoids also have beneficial effects on the liver, mainly through their antioxidant capacity and by
regulating expression of genes involved in inflammation and lipid metabolism [351]. Furthermore,
many other natural products present in the diet confer hepatoprotective effects by mechanisms related
to improved gut dysbiosis and ameliorated intestinal barrier permeability, and inhibiting steatosis by
mechanisms acting on inflammation, oxidative stress, fibrosis, and apoptosis [286].
4.3. Gut Microbiota and Dietary Antioxidants in NAFLD
Natural dietary supplements can support microbiota homeostasis or improve it when it
is disturbed [286,287]. The use of probiotics (Lactobacillus and Bifidobacterium) can ameliorate
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NAFLD [352–355]. Similarly, liver health can be supported by well-planned consumption of several
classes of food-derived compounds that are possibly involved in microbiota maintenance. Among these
are functional oligosaccharides (fructo-oligosaccharides, galacto-oligosaccharides, and chitosan
oligosaccharides) [275,356,357]. Dietary fiber is another, catabolized through fermentation by the lower
gastrointestinal tract microbiota to short-chain FAs comprising butyrate, propionate, and acetate that
ameliorate NAFLD pathogenesis [358,359]. The microbiota can convert functional amino acids, such as
L-tryptophan, to indoles and its derivatives, which improve gut and liver health. In preclinical studies,
oral administration of another amino acid, L-glutamine, has been proved protective against diet-induced
NASH progression [287,360]. Carotenoids improve the gut barrier and immune homeostasis and,
as noted, are known for their anti-inflammatory and antioxidant properties [361]. Polyphenols repress
insulin resistance, oxidative stress, and inflammation and stimulate FA β-oxidation, which collectively
confer a protective effect against NAFLD. The ω-3 PUFAs have a broad range of beneficial effects
in preclinical and clinical studies in preventing or treating NAFLD. They improve intestinal barrier
integrity and thus reduce bacterial translocation, ameliorate bile acid homeostasis, and repress liver
inflammation via activation of the nuclear farnesoid X receptor [287].
These effects of various compounds in interaction with the gut microbiota indicate that nutritional
interventions offer promise in NAFLD/NASH prevention and treatment and that their implementation
will evolve toward personalized dietary therapies with consideration of each patient’s genomic,
metabolic, and microbiotic profile. The doses of individual micronutrients appear to be important,
with some doses offering benefits and others resulting in side effects [72]. In addition, oxidative stress
is an important factor in cancer initiation but may also offer some beneficial toxicity against cancer
cells. Thus, antioxidants could have harmful effects in patients with HCC, for instance. More studies
investigating the long-term effects and outcomes in patients with advanced NASH and liver cancer are
needed [362].
5. Oxidative Stress in NAFLD: Role of Pesticides
Insecticides, herbicides, and fungicides have shown pro-oxidative properties in various
organs and tissues, including the liver (Table 3). Among the insecticides, neonicotinoid,
pyrethroid, organophosphorus, and organochlorine compounds are the most often studied.
Neonicotinoid-associated effects in various organs include the production of ROS [183], and reactive
nitrogen species (RNS) [363]. Studies assessing the role of oxidative stress in permethrin- and
deltamethrin-induced toxicity in animal models concluded that the toxicity of these compounds is
mainly the result of their pro-oxidative properties. Consistent with this finding, natural antioxidants
diminish deltamethrin-induced oxidative stress damage [364,365]. Permethrin-mediated ER stress
was recently reported in hepatic cell lines [366]. Other pyrethroid pesticides also exhibit pro-oxidative
properties in the liver, as shown in Table 3 [367–371], and various organophosphorus and organochlorine
insecticides cause oxidative stress in animal liver [136,183,371,372]. Furthermore, several studies
have reported the pro-oxidative properties of some herbicides [151,153,154,221,373–376] and chemical
families of fungicides (carbamate, benzimidazole, strobilurin, azoles, triazoles [159,377–383]) (Table 3).
Liver oxidative stress is also reported in animals exposed to a mixture of pesticides [168,193,384]
(Tables 1 and 3). Collectively, these data underscore the pro-oxidative properties of insecticides,
herbicides, and fungicides.
ROS can be produced from several sources during metabolism, as a result of biotransformation
reactions of pesticides (herbicides, insecticides, fungicides, miticides) by CYP450 enzymes, which
catalyze the oxidation reactions [192,385–387]. For example, oxidative stress generated by exposure
to the insecticide permethrin is linked to the detoxifying activities of CYP450 enzymes, and other
enzymes involved in oxidation and hydrolysis processes [364]. Organochlorine compounds such as
DDT lead to an increased ROS production through activation of CYP450 gene expression involved in its
detoxifying pathway in exposed rat liver [211]. The biotransformation reactions of organophosphorus
compounds, during which an excess of free radicals is generated, also produces ROS [187].
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Table 3. Impact of pesticide exposure on oxidative stats in in vivo models. Acceptable Daily Intake (ADI) values were from https://ephy.anses.fr/ and https:
//ec.europa.eu/food/plant/pesticides/eu-pesticides-database/. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BW, body weight; CYP, cytochrome
P450; EROD, ethoxyresorufin-O-deethylase; MDA, malondialdehyde; GPX, glutathione peroxidase; GSH, reduced glutathione; GSSG, oxidized glutathione;
GST, glutathione-S-transferase; IL-1 IL-6, Interleukin 1 and 6; ROS, reactive oxygen species; SIRT, sirtuin; SOD, superoxide dismutase; TNFα, Tumor necrosis factor α.





• Pesticide in water at 0.1 to 4 µg/L
for 4 days
• Changes in MDA content and in antioxidant




• Daily oral gavage at 5 mg/kg BW
for 2, 4, or 6 weeks
• Increased hepatic ROS, GSH, and MDA
levels (1S-cis enantiomer)





• Male and female rats
• Daily gavage with 5.8 mg/kg BW
for 20 or 30 days
• Increased liver MDA content
• Decreased liver antioxidant enzymes activity
(at 30 days)
[369]
• Male and female mice
• Daily intraperitoneal injection of 2,
4, or 8 mg/kg BW for 7 days
• Increased MDA and ROS levels, and SOD
activity at 4 or 8 mg/kg BW [370]
Insecticide Pyrethroid Lambda-cyhalothrin(0.0025)
• Male rats
• Daily oral gavage with 1, 2, 4, or 8
mg/kg for 6 consecutive days
• Increased total hepatic CYP content and
EROD activities
• Decreased GST and GPX and increased SOD
2 enzyme activities
• Increased expression of CYP genes and genes
involved in inflammatory processes,
oxidative stress, and apoptosis








• Male rats fed a pesticide-enriched
diet for 16 weeks containing either
to chlorpyrifos alone (1 or 15 mg/kg
food/day) or deltamethrin alone (5
or 35 mg/kg food/day) or the
mixture of chlorpyrifos and
deltamethrin at 1 mg/kg/day or 5
mg/kg/day
• Increased hepatic MDA content
• Changes in antioxidant enzyme activities in
rat fed CPF- or DTM- or
mixture-enriched diet
[371]
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• Intraperitoneal injection every 2 days of 50
mg/kg BW in the presence of absence of 20
mg/kg BW quercetin for 15 days
• Increased liver MDA content
• Increased H2O2 generation
• Decreased liver metallothionein content
• Decreased enzymatic antioxidant activity
and non-enzymatic component level




• Oral daily gavage with 5, 50, or 500 mg/kg
BW for 25 days
• Increased serum MDA level at 50 mg/kg BW
• Decreased hepatic SOD activity and
increased H2O2 production at the highest
assessed dose
• Increased liver IL-1, IL-6, TNF-alpha, GPX2,
caspase, and SIRT1 mRNA levels
[153]
• Male rats
• Oral exposure to Roundup through drinking
water (0.05 µg/L glyphosate) for 2 years
• Induction of oxidative stress (glutathione
metabolism) determined through analysis of





• A 30-min exposure to 2.7%, 5.5%, or 9.8%
glyphosate formulation (TouchDown
containing 52.3% glyphosate)
• Inhibition of the mitochondrial electron
transport chain
• Inhibition of proton gradient
• Inhibition of ATP and H2O2 production




• Daily intraperitoneal injection of 100 to 200
mg/kg BW for 1 week
• Decreased BW
• Slight but significant increase in hepatic SOD







• Daily oral gavage with 15, 75, or 150 mg/kg
BW for 28 days
• Increased liver weight
• Increased serum levels of TG and
low-density lipoprotein cholesterol
• Increased levels of saturated fatty acid and
decreased levels of unsaturated fatty acid





• Male rat isolated mitochondria
• Exposure to 1 to 100 µM
• Impairment of oxidative phosphorylation
• Mitochondrial swelling






• Daily oral gavage at 62.5, 125, or 250 mg/kg
BW for 14 days
• Decreased liver glutathione content
• Decreased liver SOD, catalase, and
GST activities
[154]
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Table 3. Cont.
Type of Pesticide Chemical Family Active Substances(ADI mg/kg BW/day) Experimental Model Oxidative Impacts Refs.
Fungicide Carbamate Thiophanate-methyl(0.08)
• Male rats
• Single intraperitoneal injection of 300 to 500
mg/kg BW
• Observations 3 days later
• Increased antioxidant enzyme activity
• Decreased liver GSH and vitamin C levels [388]
Strobilurin Azoxystrobin(0.2)
• Male and female zebrafish
• Dilution in water at 1, 10, or 100 µg/L
• 28 days of exposure
• Induced liver ROS production and
MDA level
• Changes in antioxidant enzymes activities
[378]
Strobilurin Azoxystrobin (0.2) orpicoxystrobin (0.043)
• Zebrafish fertilized eggs exposed in water to
0.25, 2.5, 25, or 250 mg/L azoxystrobin and 0,
0.02, 0.2, 2, or 20 mg/L picoxystrobin for 24,
48, 72, 96, or 144 h
• Adult male and female zebrafish exposed for
28 days to the above doses
• Significant increased antioxidant enzyme
and detoxifying enzyme activities
• Increased content of MDA in the larval
zebrafish study
• The effect on activities of the antioxidant and
detoxification enzymes differed between the
sexes in adult zebrafish liver, with male





• Daily gavage at the equivalent level of no
observed effects level X1, X3, or X5 for
28 days





• Pesticide-enriched diet (2500 ppm) or
intraperitoneal injections for 4 days
• Decreased GSH/GSSG ratio
• Decreased cytochrome c reductase activity
• Increased protein oxidation
[381]
• Male mice
• Pesticide-enriched diet at 500, 1250, or 2500
ppm for 4 days
• Reduced glutathione levels




• Daily oral gavage at 10, 25, or 50 mg/kg
peroral for 28 days
• Increased hepatic levels of various
CYP proteins
• Increased antioxidant enzyme activities




• Environmental doses in drinking water for
15 weeks
• Increased levels of ROS and MDA
• Changes in SOD activity
• Decreased level of GSH in the liver
[159]
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Table 3. Cont.
Type of Pesticide Chemical Family Active Substances(ADI mg/kg BW/day) Experimental Model Oxidative Impacts Refs.
Fungicide Dithiocarbamate Maneb(0.05)
• Female mice
• Daily intraperitoneal injections to 1/2, 1/4, 1/6,
or 1/8 of the LD50 for 7 days
• BW loss
• Increased serum AST and ALT activities
• Decreased serum high-density lipoprotein
cholesterol and increased cholesterol and
low-density lipoprotein cholesterol
• Increased liver MDA level and
H2O2 generation
• Decreased GPX, SOD2, and catalase activity









• Orally exposed during 7 day to 50 mg/kg
BW/day chlorpyrifos and 10 mg/kg
BW/day carbendazim
• Decreased enzymatic activity and
non-enzymatic antioxidant component levels [384]
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Moreover, all mitochondrial complexes, except complex IV, are targets of at least one pesticide
family (Table 4). In chloroplasts, herbicides are photosynthesis inhibitors and mediate their actions
by inhibiting the electron transport chain. Some functional similarity between plant chloroplasts and
mammalian mitochondria may explain the mitochondrial toxicity of the herbicide triazine, which in
plants inhibits the photosynthetic process that it targets [147]. Indeed, the triazine herbicide blocks
the activity of the oxidative phosphorylation complex I, the NADH dehydrogenase complex, in an
animal model (Table 4) [148]. Atrazine inhibits complexes III and V [148,389]. Other herbicides
such as Diuron and glyphosate inhibit complex III [390,391]. Organochlorine insecticides affect
complexes II and III, which contain the enzyme succinate dehydrogenase, and causes inhibition of
succinate translocation, likely explaining insecticide suppression of mitochondrial respiration [392].
Organophosphate insecticides inhibit mitochondrial complex I in birds [393], and effects on complex
IV and/or V have been reported in mammalian models [394,395]. Complex V is also inhibited by
imidacloprid, abamectin, and DDE [392,396,397].
The strobilurin family of fungicides, known as succinate dehydrogenase inhibitors (SDHIs),
inhibits fungus mitochondrial respiration via blockade of electron transfer between cytochrome b
and cytochrome c1, which results in oxidative stress [378]. In addition to the inhibitory effect on
succinate dehydrogenase, other SDHI fungicides inhibit complex III (ubiquinol cytochrome c reductase)
with varying efficiency in human and animal cells [184,381,398,399]. The herbicide glyphosate
targets the mitochondrial electron transport chain in duckweed, in particular complex III, resulting
in ROS production; however, its impact on mammalian mitochondria is not yet documented [400].
Some pesticides may affect more than one mitochondrial complex [148,395] (Table 4). For example,
SDHI fungicides act on mitochondrial complexes I, II, and III (Table 4). In brief, various chemical
families of insecticides, except DDE, alter complex V, whereas rotenone and malathion act on complexes
I and II and I, IV, and V, respectively. Fungicides affect complexes II and III of the mitochondrial
respiratory chain, and herbicides target complexes I, III, and V (Table 4). It is noteworthy that some
fungicides (fludioxonil and Maneb) and the herbicide paraquat induce oxidative stress by acting on
both mitochondria complexes and cytosolic NADPH oxidase [401,402].
Pesticide exposure affects antioxidant enzyme expression and/or activity and/or levels of
antioxidant compounds such as GSH (Table 3). Pesticides can influence antioxidant pathways
by modifying the expression of Nrf2. In HepG2 cells, DDE exposure decreases Nrf2 protein level
and subsequently glutamyl-cysteine synthase activity [403]. Changes in Nrf2 promoter methylation
have been identified in germ cells from adult mice exposed to the herbicide methyl-parathion for
5 days [404]. The exposure of rats to the pyrethroid insecticide bifenthrin for 60 days at a high dose led
to an induction in gene expression, including of Nrf2, in the hippocampus [405], and the fungicide
prochloraz induced Nrf2 activity in a gene reporter assay [406]. Exposure to pesticides such as atrazine,
chlorpyrifos, zinc dimethyldithiocarbamate, vinclozolin, paraquat, and rotenone alters Sirt expression
(mainly Sirt1, 3, and 6)—all members of a NAD+-dependent type III deacetylase enzyme family
considered to operate as stress adaptors under oxidative, genotoxic, and metabolic stresses [407–413].
The mitochondrial scavenger of ROS, UCP-2, is also induced by the organochlorine pesticide DDE [203].
Pesticides induce ER stress in association with the development of some pathologies but without
metabolic disturbance [414]. Additionally, the antiparasitic niclosamide induces ROS generation that
enhances ATF3 and CHOP expression and ER stress in hepatoma HepG2 cells [415]. However, the
pyrethroid insecticide permethrin induces ROS production without inducing ER stress in HepG2
cells [366]. Altogether, these findings indicate that pesticides affect several processes that result in
oxidative stress: the CYP450 system, mitochondrial respiration, antioxidant pathways, the stress
adaptor system, and scavenger ROS activity.
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Azoxystrobin x Rat liver, isolated mitochondria [184]





x x Exposed HEK cells [399]
Antiparasitic Abamectin x Rat liver, isolated mitochondria [396]
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Besides oxidative stress, pesticide exposure may lead to NAFLD through their impact on lipid
metabolism by (i) modifying fatty acid uptake and efflux [171] and modulating FFA transport as
described for insecticides and herbicides, (ii) increasing lipogenesis ([173,406] (Table 1), (iii) altering
oxidation pathways [175]; insecticides, herbicides, and fungicides affect both β-oxidation and
lipogenesis (Tables 1 and 2), (iv) interacting with nuclear receptors [416–421] involved in the control of
metabolism as demonstrated for pyrethroid and neonicotinoid insecticides [176–178], and imidazole or
triazole fungicides [158,382] or a pesticide mixture [193], but implication in NAFLD is not proven.
Some pesticides may ameliorate lipid metabolism. For example, environmental doses of Boscalid,
a widely used fungicide, induce gene expression that promotes β-oxidation and inhibits lipogenesis
in the zebrafish liver [179]. Similarly, oral exposure to the carbamate fungicide propamocarb in mice
during a 4-week period leads to a down regulation of genes involved in glycolysis, TG, and fatty acid
synthesis in the liver [180]. Pesticide alter glucose metabolism through activation of glucose uptake,
glycogenolysis, gluconeogenesis (as reviewed for insecticides in [136]) or through inhibition of the
mitochondrial respiratory complex (Table 4), and modulation of Chrebp gene expression levels [185],
change in the expression of PPARβ/δ and genes involved in glucose metabolism (FoxO1 and CREB) [186].
Pesticides also induce insulin resistance by acting on insulin signaling pathways (for a review
see [192]). Liver inflammation was also reported upon exposure to organophosphorus [188], OC [189],
neonicotinoid [142,143] pyrethroid insecticides [144], or to triazole or imidazole fungicides [190]
(Table 1).
In summary this section on the role of pesticides in oxidative stress in NAFLD shows that
pesticides are pro-oxidant compounds that can induce ROS production through various mechanisms:
(i) detoxification via P450-dependent processes, (ii) effects on mitochondrial respiratory complexes, and
(iii) action on Sirt- and or Nrf2-dependent antioxidant responses (Figure 8). It is noteworthy that the
data do not consistently come from studies performed in the liver and/or related to a metabolic impact
of pesticides. Although pesticide exposure and NAFLD are not clearly correlated, the prooxidative
properties of pesticides as well as their impact on various pathways involved in the regulation
of metabolic homeostasis support their putative role in the development or in the progression of
hepatopathy. Moreover, various experimental studies showed that pesticides could affect various
pathways involved in the regulation of metabolic and hepatic homeostasis strongly suggesting their
role in NAFLD. Pesticides affect oxidative stress in NAFLD, but in many studies (reported in Tables 1
and 2), animals were exposed to high doses of pesticide and durations of exposure that are not
relevant for human exposure, making any human translation of results difficult. In fact, to better
decipher the role of pesticide-induced oxidative stress in the development of NAFLD, more studies
are needed that link different pesticide cellular targets and/or mechanisms of action underlying
ROS production with hepatic processes involved in the control of energy metabolism, such as lipid
metabolism, inflammation, and gene regulation by nuclear receptors. Interestingly, nuclear receptors,
such as PPARs, progesterone receptor (PR), mineralocorticoid receptor (MR), glucocorticoid receptor
(GR), aryl hydrocarbon receptor (AhR), retinoic acid receptors (RARs), farnesoid X receptor (FXR),
and liver X receptors (LXRs) are established or suspected targets of endocrine disrupting chemicals
including diverse agrochemicals, but further analyses are needed to determine whether this can lead
to the development of NAFLD/NASH [410,411].
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6. Conclusions
Many challenges remain in understanding the etiology of NAFLD because the precise staging of
its progression in the absence of liver biopsy is not yet possible. Furthermore, no therapy has been
approved by the U.S. Food and Drug Administration, and lifestyle modifications (diet, exercise) are
difficult to implement and adhere to, which has contributed to the failure to reduce NAFLD prevalence.
In terms of implemented therapeutic interventions, vitamin E and the PPARγ ligand pioglitazone
have beneficial effects on steatosis and inflammation, but they do not improve fibrosis, the strongest
indicator of mortality in NAFLD/NASH. However, sustained research has led to a better understanding
of the pathogenesis and progression of this condition and to the development of promising compounds
to block and possibly reverse fibrosis, which are presently in clinical trials [348,412]. It is well accepted
that disturbances in lipid metabolism are key to the development of NAFLD and its progression.
They can affect different ROS generators, such as mitochondria, ER, and NOX [226]. Although many
aspects of the contributions of ROS generators to NAFLD remain unexplored, much progress has been
made in understanding how increased ROS levels trigger changes in insulin sensitivity, the activity of
key enzymes of lipid metabolism, innate immune system signaling, and the level of inflammatory
responses. Both macro- and micronutrients impact oxidative stress in NAFLD pathogenesis. An excess
of certain macronutrients, such as cholesterol and fructose, exerts pro-oxidant effects, whereas several
micronutrients have the potential to decrease NAFLD through their antioxidant properties. However,
human diets are complex, and it is challenging to mimic them in experimental models. The contribution
of specific dietary nutrients to oxidative stress in NAFLD is not fully elucidated and needs further
research. It is noteworthy that epidemiological studies did not report a correlation between pesticide
exposure and NAFLD in human. However, pesticides exposure was correlated in occupationally
exposed population with metabolic disorders. Moreover, various experimental studies showed that
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pesticides can affect various pathways involved in the regulation of metabolic and hepatic homeostasis
strongly suggesting a role in NAFLD. Pesticides affect oxidative stress in NAFLD, but in many studies
(reported in Tables 1 and 2), animals were exposed to high doses of pesticide and durations of exposure
that are not relevant for human exposure, making any human translation of results difficult. In rodents,
perinatal exposure to organophosphorus insecticides worsens metabolic perturbations induced by
HFD [197] or by overfeeding [198,206]. The lifelong effects of perinatal exposure with respect to
NAFLD/NASH development, and health in general, remain an open and crucial area of research.
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